CHC HEALTHCARE GROUP

PARENT COMPANY ONLY

FINANCIAL STATEMENTS AND INDEPENDENT

AUDITORS' REPORT

DECEMBER 31, 2025 AND 2024

For the convenience of readers and for information purpose only, the auditors’ report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors’ report and financial statements shall prevail.

~1~

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of CHC Healthcare Group

Opinion

We have audited the accompanying parent company only balance sheets of CHC Healthcare Group (the “Company”) as at December 31, 2025 and 2024, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors’ responsibilities for the audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company’s 2025 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Company’s 2025 parent company only financial statements are stated as follows:

Assessment of investments accounted for using equity method

Refer to Note 4(9) for accounting policy on investments accounted for using equity method, Note 5(2) for uncertainty of accounting estimates and assumptions in relation to impairment assessment of investments accounted for using equity method, and Note 6(4) for details of investments accounted for using equity method.

Impairment assessment of Treasure of Health Co., Ltd., Chiu Ho Medical System Co., Ltd., and Tomorrow Medical System Co., Ltd., the Company’s subsidiaries

As of December 31, 2025, the Company’s subsidiaries, Treasure of Health Co., Ltd. (Treasure of Health), and Chiu Ho Medical System Co., Ltd. and its subsidiaries (“Chiu Ho Medical Group”), and Tomorrow Medical System Co., Ltd. (Tomorrow Medical) recognised investments accounted for using equity method amounting to NT$6,331,849 thousand, and investment income amounting to NT$198,165 thousand for the year then ended. Because these investments constituted 63% of the Company’s total assets as of December 31, 2025, and investment income constituted 105% of the Company’s profit before tax for the year ended December 31, 2025, which are significant to the Company’s financial statements, we identified the assessment of investments accounted for using equity method as a key audit matter. Furthermore, the key audit matters identified in the subsidiaries’ financial statements (specifically impairment assessment of goodwill and property, plant and equipment) are also identified as key audit matters of the Company. The key audit matters for the year ended December 31, 2025 are stated as follows:

Impairment assessment of goodwill

Description

As of December 31, 2025, after identifying the smallest cash generating unit which can generate independent cash flows, Treasure of Heath and Chiu Ho Medical Group used the recoverable amount of each cash generating unit to assess whether goodwill arising from business combination may be impaired. Since the assumptions used by management to assess whether goodwill is impaired involve subjective judgement and have high uncertainty, we considered the impairment assessment of goodwill

as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

A. Obtained an understanding on how management identifies the objective evidence of goodwill impairment, taking into account certain factors in a consistent manner and ascertained whether the management uses reliable information.

B. Obtained the report on the valuation of the subsidiary issued by an expert appointed by the management and performed the following:

(1) Assessed the expert’s independence, objectiveness and competence by reviewing the expert’s qualification.

(2) Assessed whether the valuation model is reasonable based on our knowledge of Treasure of Health and Chiu Ho Medical Group’s businesses and industry.

(3) Confirmed whether the expert uses the same future cash flows relative to the budget for the future years provided by the management.

(4) Checked whether the comparable assets adopted in the appraisal report are consistent with the actual operations.

(5) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Assessment of Reasonableness of Purchase Price Allocation for Business Combination

Description

On November 1, 2024, the Company’s subsidiary, Treasure of Health, acquired 51% of the share capital of Happy Health Co., Ltd. (Happy Health) for a cash consideration of NT$71,400 thousand. This investment is accounted for using the equity method by the Company. The allocation of the purchase price to the net fair value of identifiable assets and liabilities acquired and goodwill of the investee company for this acquisition is based on management's assessment, which involves accounting estimates and assumptions. Since the net fair value of the investee’s identifiable assets and liabilities, as well as goodwill, were finalized in the third quarter of 2025, we have identified the purchase price allocation for the aforementioned equity interest as one of our key audit matters.

~3~

Refer to Note 4(32) for the accounting policy on business combinations, and Note 6(32) for related details.

How our audit addressed the matter

In addition to understanding management's basis and procedures for the purchase price allocation, we also reviewed the fair value assessment methods for identifiable assets and liabilities assumed, as presented in the purchase price allocation report prepared by experts commissioned by Treasure of Health, and the reasonableness of the key assumptions used in the future cash flow forecasts for identifiable intangible assets and the fair value calculation methods to determine goodwill. Our procedures included:

A. Verifying the parameters and calculation formulas used in the valuation model.
B. Comparing the projected growth rates and operating net margins used with historical results, economic forecasts, and industry outlook reports.
C. Comparing the discount rates used with the cost of capital assumptions for cash-generating units and the rates of return for similar assets.

Impairment assessment of property, plant and equipment

Description

Due to fierce competition in the healthcare industry, certain leasing businesses of CHC Healthcare Group (the "Group") did not achieve expected profitability. The Group assesses the impairment based on the estimated recoverable amounts of leased assets (shown as property, plant and equipment) where there is an indication that they are impaired. Given that the calculation of recoverable amounts requires significant accounting estimates relying on subjective judgement and a high degree of uncertainty, we considered the impairment assessment of leased assets as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

A. Obtained an understanding on how management identifies the objective evidence of impairment, taking into account certain factors in a consistent manner and ascertained whether the management uses reliable information.

B. Acquired the asset appraisal report issued by an expert appointed by the management and performed the following:

(1) Assessed the independence, objectiveness and competence by reviewing the expert’s qualification.

(2) Assessed whether the valuation method is widely adopted and appropriate based on our knowledge of the Group’s businesses and industry.

(3) Confirmed whether the replacement cost, comparative objects and the assets’ use indicated on the appraisal report are consistent with the actual operations.

(4) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Responsibilities of management and those charged with governance for the parent company only financial statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal controls as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company’s financial reporting process.

Auditors’ responsibilities for the audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit conducted in accordance with the Standards of Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud

~5~

or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

A. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.

B. Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal controls.

C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

D. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

E. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

F. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

~6~

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the current period and are therefore the key audit matters. We describe these matters in our auditors’ report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For and on behalf of PricewaterhouseCoopers, Taiwan
March 10, 2026

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and independent auditors’ report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

~7~

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Assets	Notes	December 31, 2025		December 31, 2024
			Amount	%	Amount	%
Current assets
1100	Cash and cash equivalents	6(1)	$ 267,596	3	$ 156,244	2
1110	Financial assets at fair value through profit or loss - current	6(2)	15,996	-	49,669	-
1210	Other receivables due from related parties	7	1,105,001	11	436,112	5
1220	Current tax assets		102	-	102	-
1410	Prepayments		1,069	-	5,706	-
11XX	Total current assets		1,389,764	14	647,833	7
Non-current assets
1510	Financial assets at fair value through profit or loss - non-current	6(2)	43,643	-	9,081	-
1517	Financial assets at fair value through other comprehensive income - non-current	6(3)	14,513	-	12,724	-
1550	Investments accounted for using equity method	6(4)	8,601,685	85	8,508,424	92
1600	Property, plant and equipment		616	-	608	-
1755	Right-of-use assets	6(5)	16,633	-	23,516	-
1840	Deferred tax assets	6(20)	57,032	1	58,616	1
1900	Other non-current assets		359	-	572	-
15XX	Total non-current assets		8,734,481	86	8,613,541	93
1XXX	Total assets		$ 10,124,245	100	$ 9,261,374	100

(Continued)

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(EXRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Liabilities and Equity	Notes	December 31, 2025		December 31, 2024
		Amount	%	Amount	%
Current liabilities
2100	Short-term borrowings	6(6)	$ 200,000	2	$ 250,000	3
2150	Notes payable		135	-	135	-
2200	Other payables		18,540	-	22,097	-
2220	Other payables due from related parties	7	21,146	-	-	-
2230	Current tax liabilities		17,146	-	1,774	-
2280	Lease liabilities - current	7	6,955	-	6,828	-
2320	Long-term liabilities, current portion	6(7)(8)	247,800	3	1,306,507	14
2399	Other current liabilities		939	-	997	-
21XX	Total current liabilities		512,661	5	1,588,338	17
Non-current liabilities
2500	Financial liabilities at fair value through profit or loss - non-current	6(2)	11,340	-	-	-
2530	Bonds payable	6(7)	803,510	8	-	-
2540	Long-term borrowings	6(8)	1,156,400	12	1,352,000	15
2570	Deferred tax liabilities	6(20)	734	-	734	-
2580	Lease liabilities - non-current	7	10,076	-	17,031	-
25XX	Total non-current liabilities		1,982,060	20	1,369,765	15
2XXX	Total liabilities		2,494,721	25	2,958,103	32
Equity
	Share capital	6(7)(10)(11)
3110	Common stock		1,953,110	19	1,668,651	18
	Capital surplus	6(7)(10)(12)
3200	Capital surplus		4,858,430	48	3,732,745	40
	Retained earnings	6(13)
3310	Legal reserve		486,240	5	469,411	5
3320	Special reserve		395,141	4	385,664	4
3350	Unappropriated retained earnings		349,945	3	441,941	5
	Other equity	6(3)
3400	Other equity		( 413,342)	( 4)	( 395,141)	( 4)
3XXX	Total equity		7,629,524	75	6,303,271	68
	Significant contingent liabilities and unrecognised contract commitments	9
	Significant events after the balance sheet date	11
3X2X	Total liabilities and equity		$ 10,124,245	100	$ 9,261,374	100

The accompanying notes are an integral part of these parent company only financial statements.

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT FOR EARNINGS PER SHARE AMOUNTS)

	Items	Notes	2025		2024
			Amount	%	Amount	%
4000	Operating revenue	6(14) and 7	$ 344,550	100	$ 334,154	100
5000	Operating costs	6(5)(9)(10)(19)	( 108,881)	( 32)	( 122,032)	( 37)
5900	Gross profit		235,669	68	212,122	63
	Non-operating income and expenses
7100	Interest income	6(15) and 7	14,289	4	9,037	3
7010	Other income	6(16)	22	-	339	-
7020	Other gains and losses	6(2)(17)	( 4,449)	1	4,032	1
7050	Finance costs	6(5)(18)	( 57,672)	( 17)	( 55,159)	( 16)
7000	Total non-operating income and expenses		( 47,810)	( 14)	( 41,751)	( 12)
7900	Profit before income tax		187,859	54	170,371	51
7950	Income tax expense	6(20)	( 1,582)	-	( 1,987)	-
8200	Profit for the year		$ 186,277	54	$ 168,384	51
	Other comprehensive income
	Components of other comprehensive income that will not be reclassified to profit or loss
8316	Unrealised gains from investments in equity instruments measured at fair value through other comprehensive income	6(3)	$ 1,789	1	$ 2,565	1
8330	Share of other comprehensive loss of associates and joint ventures accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss		( 17,716)	( 5)	-	-
	Components of other comprehensive income that will be reclassified to profit or loss
8361	Financial statements translation differences of foreign operations		( 2,304)	( 1)	14,608	4
8380	Share of other comprehensive income (loss) of associates and joint ventures accounted for using equity method, components of other comprehensive income that will be reclassified to profit or loss		30	-	( 5)	-
8300	Other comprehensive (loss) income for the year		($ 18,201)	( 5)	$ 17,168	5
8500	Total comprehensive income for the year		$ 168,076	49	$ 185,552	56
	Earnings per share (in dollars)
9750	Basic earnings per share	6(21)	$ 1.00		$ 1.01
9850	Diluted earnings per share	6(21)	$ 1.00		$ 0.98

The accompanying notes are an integral part of these parent company only financial statements.

~10~

CHC HEALTHCARE GROUP

PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY

YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	Common stock	Capital Reserves			Retained Earnings			Other Equity Interest			Total equity
			Capital surplus	Employee stock warrants	Others	Legal reserve	Special reserve	Unappropriated retained earnings	Financial statements translation differences of foreign operations	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Others
2024
Balance at January 1, 2024		$ 1,664,194	$ 3,659,068	$ 1,731	$ 55,857	$ 427,524	$ 387,424	$ 648,281	( $ 41,008 )	( $ 344,656 )	$ -	$ 6,458,415
Profit for the year		-	-	-	-	-	-	168,384	-	-	-	168,384
Other comprehensive income		-	-	-	-	-	-	-	14,603	2,565	-	17,168
Total comprehensive income		-	-	-	-	-	-	168,384	14,603	2,565	-	185,552
Appropriations of 2023 earnings	6(13)
Legal reserve		-	-	-	-	41,887	-	( 41,887 )	-	-	-	-
Cash dividends		-	-	-	-	-	-	( 334,502 )	-	-	-	( 334,502 )
Reversal of special reserve		-	-	-	-	-	( 1,760 )	1,760	-	-	-	-
Conversion of convertible bonds	6(7)(11)	4,157	15,943	-	( 330 )	-	-	-	-	-	-	19,770
Exercise of employee stock options	6(10)(11)	300	803	( 327 )	-	-	-	-	-	-	-	776
Compensation cost of employee stock options of subsidiaries		-	-	-	1,948	-	-	-	-	-	-	1,948
Disposal of subsidiaries		-	-	-	( 1,948 )	-	-	( 95 )	-	-	-	( 2,043 )
Redemption liabilities of subsidiaries		-	-	-	-	-	-	-	-	-	( 26,645 )	( 26,645 )
Balance at December 31, 2024		$ 1,668,651	$ 3,675,814	$ 1,404	$ 55,527	$ 469,411	$ 385,664	$ 441,941	( $ 26,405 )	( $ 342,091 )	( $ 26,645 )	$ 6,303,271
2025
Balance at January 1, 2025		$ 1,688,651	$ 3,675,814	$ 1,404	$ 55,527	$ 469,411	$ 385,664	$ 441,941	( $ 26,405 )	( $ 342,091 )	( $ 26,645 )	$ 6,303,271
Profit for the year		-	-	-	-	-	-	186,277	-	-	-	186,277
Other comprehensive income (loss)		-	-	-	-	-	-	-	( 2,274 )	( 15,927 )	-	( 18,201 )
Total comprehensive income (loss)		-	-	-	-	-	-	186,277	( 2,274 )	( 15,927 )	-	168,076
Appropriations of 2024 earnings	6(13)
Legal reserve		-	-	-	-	16,829	-	( 16,829 )	-	-	-	-
Cash dividends		-	-	-	-	-	-	( 251,967 )	-	-	-	( 251,967 )
Special reserve		-	-	-	-	-	9,477	( 9,477 )	-	-	-	-
Conversion of convertible bonds	6(7)(11)	284,241	1,039,242	-	( 21,502 )	-	-	-	-	-	-	1,301,981
Issuance of convertible bonds	6(7)	-	-	-	100,170	-	-	-	-	-	-	100,170
Exercise of employee stock options	6(10)(11)	218	566	( 1,404 )	1,175	-	-	-	-	-	-	555
Changes in ownership interests in subsidiaries		-	-	-	7,438	-	-	-	-	-	-	7,438
Balance at December 31, 2025		$ 1,953,110	$ 4,715,627	$ -	$ 142,808	$ 486,240	$ 395,141	$ 349,945	( $ 28,679 )	( $ 358,018 )	( $ 26,645 )	$ 7,629,524

The accompanying notes are an integral part of these parent company only financial statements.

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES
Profit before tax		$ 187,859	$ 170,371
Adjustments
Adjustments to reconcile profit (loss)
Depreciation charge	6(19)	7,208	7,206
Amortisation charge	6(19)	213	197
Net loss (gain) on financial assets or liabilities at fair value through profit or loss	6(2)(17)	4,449	( 4,030 )
Interest expense	6(18)	42,665	45,924
Interest income	6(15)	( 14,289 )	( 9,037 )
Dividend income	6(16)	( 10 )	( 330 )
Share of profit of associates and joint ventures accounted for using equity method	6(14)	( 203,090 )	( 194,764 )
Amortisation of discount on bonds payable	6(18)	15,007	9,235
Changes in operating assets and liabilities
Changes in operating assets
Financial assets at fair value through profit or loss		( 1,572 )	22,465
Prepayments		4,637	623
Changes in operating liabilities
Other payables		( 3,666 )	456
Other current liabilities		( 58 )	11
Cash inflow generated from operations		39,353	48,327
Interest received during the year		15,205	4,473
Dividends received during the year		261,726	328,867
Interest paid during the year		( 42,519 )	( 45,826 )
Income tax paid		( 3,285 )	( 437 )
Net cash flows used in operating activities		270,480	335,404
CASH FLOWS FROM INVESTING ACTIVITIES
Increase in other receivables due from related parties	7	( 630,000 )	( 270,000 )
Acquisition of investments accounted for using equity method	7	( 304,079 )	( 71,247 )
Proceeds from capital reduction of investments accounted for using equity method	7	139,640	136,000
Acquisition of property, plant and equipment		( 370 )	( 367 )
Increase in other non-current assets		-	( 500 )
Net cash flows used in investing activities		( 794,809 )	( 206,114 )
CASH FLOWS FROM FINANCING ACTIVITIES
Increase in short-term loans	6(22)	1,550,000	1,550,000
Decrease in short-term loans	6(22)	( 1,600,000 )	( 1,400,000 )
Payments of lease liabilities	6(22)	( 6,828 )	( 6,702 )
Proceeds from issuance of bonds	6(7)(22)	904,500	-
Repayments of bonds	6(7)(22)	( 7,484 )	-
Issuance cost of bonds payable	6(22)	( 5,295 )	-
Proceeds from long-term debt	6(22)	862,200	-
Repayments of long-term debt	6(22)	( 810,000 )	-
Exercise of employee stock options		555	776
Payment of cash dividends	6(13)	( 251,967 )	( 334,502 )
Net cash flows provided by (used in) financing activities		635,681	( 190,428 )
Increase (decrease) in cash and cash equivalents		111,352	( 61,138 )
Cash and cash equivalents at beginning of year		156,244	217,382
Cash and cash equivalents at end of year		$ 267,596	$ 156,244

The accompanying notes are an integral part of these parent company only financial statements.

CHC HEALTHCARE GROUP
NOTES TO THE PARENT COMPANY ONLY FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS,
EXCEPT AS OTHERWISE INDICATED)

HISTORY AND ORGANISATION

CHC Healthcare Group (“CHC” or the “Company”) was established in November 2009. The Company was established for the purpose of enhancing the comprehensive performance in Greater China and implementing organisational restructuring with Chiu Ho Medical System Co., Ltd. and other affiliates. The Company was listed on the Taiwan Stock Exchange on October 24, 2012. The Company is primarily engaged in holding investments in various businesses.

THE DATE OF AUTHORISATION FOR ISSUANCE OF THE PARENT COMPANY ONLY FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION

These parent company only financial statements were authorised for issuance by the Board of Directors on March 10, 2026.

APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS®”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’	January 1, 2026
Amendments to IAS 21, ‘Lack of exchangeability’	January 1, 2025

The above standards and interpretations have no significant impact to the Company’s financial condition and financial performance based on the Company’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

-13-

-14-

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-dependent electricity’	January 1, 2026
IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendments to IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 - comparative information’	January 1, 2023
Annual Improvements to IFRS Accounting Standards—Volume 11	January 1, 2026
The above standards and interpretations have no significant impact to the Company’s financial condition and financial performance based on the Company’s assessment.

(3) Effect of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’	To be determined by International Accounting Standards Board
IFRS 18, ‘Presentation and disclosure in financial statements’	January 1, 2027 (Note)
IFRS 19, ‘Subsidiaries without public accountability: disclosures’	January 1, 2027
Amendments to IAS 21, ‘Translation to a Hyperinflationary Presentation Currency’	January 1, 2027

Note: The FSC has announced in a press release on September 25, 2025 that public companies will apply IFRS 18 starting from the fiscal year 2028. Additionally, entities can choose to adopt IFRS 18 earlier based on their requirements after the FSC endorses IFRS 18.

Except for the following, the above standards and interpretations have no significant impact to the Company’s financial condition and financial performance based on the Company’s assessment. The quantitative impact will be disclosed when the assessment is complete.

IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

SUMMARY OF MATERIAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these parent company only financial statements are set out below. These policies have been consistently applied to all the periods presented,

unless otherwise stated.

(1) Compliance statement

The parent company only financial statements of the Company have been prepared in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers".

(2) Basis of preparation

A. Except for the following items, these parent company only financial statements have been prepared under the historical cost convention:

(a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.

(b) Financial assets at fair value through other comprehensive income.

B. The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Foreign currency translation

Items included in the financial statements of each of the Company's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The parent company only financial statements are presented in New Taiwan Dollars, which is the Company's functional and The Company's presentation currency.

A. Foreign currency transactions and balances

(a) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognised in profit or loss in the period in which they arise.

(b) Monetary assets and liabilities denominated in foreign currencies at the period end are re-translated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognised in profit or loss.

(c) All foreign exchange gains and losses are presented in the statement of comprehensive income within "other gains or losses".

B. Translation of foreign operations

The operating results and financial position of all the Company entities and associates that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

(a) Assets and liabilities for each balance sheet presented are translated at the closing exchange rate at the date of that balance sheet;

-15-

(b) Income and expenses for each statement of comprehensive income are translated at average exchange rates of that period; and
(c) All resulting exchange differences are recognised in other comprehensive income.

(4) Classification of current and non-current items

A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:

(a) Assets arising from operating activities that are expected to be realised, or are intended to be sold or consumed within the normal operating cycle;
(b) Assets held mainly for trading purposes;
(c) Assets that are expected to be realised within twelve months from the balance sheet date;
(d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to pay off liabilities more than twelve months after the balance sheet date.

B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:

(a) Liabilities that are expected to be paid off within the normal operating cycle;
(b) Liabilities arising mainly from trading activities;
(c) Liabilities that are to be paid off within twelve months from the balance sheet date;
(d) Liabilities for which the repayment date cannot be extended unconditionally to more than twelve months after the balance sheet date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

(5) Financial assets at fair value through profit or loss

A. Financial assets at fair value through profit or loss are financial assets that are not measured at amortised cost or fair value through other comprehensive income.
B. On a regular way purchase or sale basis, financial assets at fair value through profit or loss are recognised and derecognised using trade date accounting.
C. At initial recognition, the Company measures the financial assets at fair value and recognises the transaction costs in profit or loss. The Company subsequently measures the financial assets at fair value, and recognises the gain or loss in profit or loss.
D. The Company recognises the dividend income when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Company and the amount of the dividend can be measured reliably.

(6) Financial assets at fair value through other comprehensive income

A. Financial assets at fair value through other comprehensive income comprise equity securities which are not held for trading, and for which The Company has made an irrevocable election at initial recognition to recognise changes in fair value in other comprehensive income.

-16-

B. On a regular way purchase or sale basis, financial assets at fair value through other comprehensive income are recognised and derecognised using trade date accounting.

C. At initial recognition, The Company measures the financial assets at fair value plus transaction costs. The Company subsequently measures the financial assets at fair value:

The changes in fair value of equity investments that were recognised in other comprehensive income are reclassified to retained earnings. When the equity instruments are derecognised the cumulative gain or loss previously recognised in other comprehensive income is not reclassified from equity to profit or loss. Dividends are recognised as revenue when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Company and the amount of the dividend can be measured reliably.

(7) Impairment of financial assets

For financial assets at amortised cost including accounts receivable that have a significant financing component, at each reporting date, the Company recognises the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognises the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable or contract assets that do not contain a significant financing component, the Company recognises the impairment provision for lifetime ECLs.

(8) Derecognition of financial assets

The Company derecognises a financial asset when the contractual rights to receive the cash flows from the financial asset expire.

(9) Investments accounted for using equity method – subsidiaries

A. Subsidiaries are all entities controlled by the Company. The Company controls an entity when the Company is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.

B. Unrealised gains or losses occurred from the transactions between the Company and subsidiaries have been offset. The accounting policies of the subsidiaries are consistent with the policies adopted by the Company.

C. The Company’s share of its subsidiaries’ post-acquisition profits or losses is recognised in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income. When the Company’s share of losses in a subsidiary equals or exceeds its interest in the subsidiary, the Company continues to recognise loss proportionately to its ownership.

D. Changes in a parent’s ownership interest in a subsidiary that do not result in the parent losing control of the subsidiary (transactions with non-controlling interests) are accounted for as equity transactions, i.e. transactions with owners in their capacity as owners. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of

-17-

the consideration paid or received is recognised directly in equity.

E. When the Company loses control of a subsidiary, the Company remeasures any investment retained in the former subsidiary at its fair value. That fair value is regarded as the fair value on initial recognition of a financial asset or the cost on initial recognition of the associate or joint venture. Any difference between fair value and carrying amount is recognised in profit or loss. All amounts previously recognised in other comprehensive income in relation to the subsidiary are reclassified to profit or loss on the same basis as would be required if the related assets or liabilities were disposed of. That is, when the Company loses control of a subsidiary, all gains or losses previously recognised in other comprehensive income in relation to the subsidiary should be reclassified from equity to profit or loss, if such gains or losses would be reclassified to profit or loss when the related assets or liabilities are disposed of.

F. According to “Regulations Governing the Preparation of Financial Reports by Securities Issuers”, profit and other comprehensive income in the parent company only financial statements should be the same as profit and other comprehensive income attributable to shareholders of the parent in the consolidated financial statements, and the equity in the parent company only financial statements should be the same as the equity attributable to shareholders of the parent in the consolidated financial statements.

(10) Property, plant and equipment

A. Property, plant and equipment are initially recorded at cost. Borrowing costs incurred during the construction period are capitalised.

B. Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

C. Land is not depreciated. Other property, plant and equipment apply cost model and are depreciated using the straight-line method to allocate their cost over their estimated useful lives. Each part of an item of property, plant and equipment with a cost that is significant in relation to the total cost of the item must be depreciated separately.

D. The assets’ residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year-end. If expectations for the assets’ residual values and useful lives differ from previous estimates or the patterns of consumption of the assets’ future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, ‘Accounting Policies, Changes in Accounting Estimates and Errors’, from the date of the change.

The estimated useful lives of property, plant and equipment are as follows:

Other equipment
2 ~ 5 years

-18-

(11) Leasing arrangements (lessee) - right-of-use assets/lease liabilities

A. Leases are recognised as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Company. For short-term leases or leases of low-value assets, lease payments are recognised as an expense on a straight-line basis over the lease term.

B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are comprised of fixed payments, less any lease incentives receivable.

The Company subsequently measures the lease liability at amortised cost using the interest method and recognises interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognised as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.

C. At the commencement date, the right-of-use asset is stated at cost comprising the following:

(a) The amount of the initial measurement of lease liability;
(b) Any lease payments made at or before the commencement date; and
(c) Any initial direct costs incurred by the lessee.

The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognised as an adjustment to the right-of-use asset.

(12) Impairment of non-financial assets

The Company assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. When the circumstances or reasons for recognising impairment loss for an asset in prior years no longer exist or diminish, the impairment loss is reversed. The increased carrying amount due to reversal should not be more than what the depreciated or amortised historical cost would have been if the impairment had not been recognised.

(13) Borrowings

Borrowings comprise long-term and short-term bank borrowings. Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method.

-19-

(14) Convertible bonds payable

Convertible bonds issued by the Company contain conversion options (that is, the bondholders have the right to convert the bonds into the Company’s common shares by exchanging a fixed amount of cash for a fixed number of common shares), call options and put options. The Company classifies the bonds payable upon issuance as a financial asset, a financial liability or an equity instrument in accordance with the contract terms. They are accounted for as follows:

A. The embedded call options and put options are recognised initially at net fair value as ‘financial assets or financial liabilities at fair value through profit or loss’. They are subsequently remeasured and stated at fair value on each balance sheet date; the gain or loss is recognised as ‘gain or loss on valuation of financial assets or financial liabilities at fair value through profit or loss’.

B. The host contracts of bonds are initially recognised at fair value. Any difference between the initial recognition and the redemption value is accounted for as the premium or discount on bonds payable and subsequently is amortised in profit or loss as an adjustment to ‘finance costs’ over the period of circulation using the effective interest method.

C. The embedded conversion options which meet the definition of an equity instrument are initially recognised in ‘capital surplus-share options’ at the residual amount of total issue price less the amount of financial assets or financial liabilities at fair value through profit or loss and bonds payable as stated above. Conversion options are not subsequently remeasured.

D. Any transaction costs directly attributable to the issuance are allocated to each liability or equity component in proportion to the initial carrying amount of each abovementioned item.

E. When bondholders exercise conversion options, the liability component of the bonds (including bonds payable and ‘financial assets or financial liabilities at fair value through profit or loss’) shall be remeasured on the conversion date. The issuance cost of converted common shares is the total book value of the abovementioned liability component and ‘capital surplus - share options’.

(15) Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability specified in the contract is discharged or cancelled or expires.

(16) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognised as expenses in that period when the employees render service.

B. Pensions

For defined contribution plans, the contributions are recognised as pension expenses when they are due on an accrual basis. Prepaid contributions are recognised as an asset to the extent of a cash refund or a reduction in the future payments.

-20-

C. Employees' compensation and directors' remuneration

Employees' compensation and directors' remuneration are recognised as expenses and liabilities, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates. If employee compensation is distributed by shares, the Company calculates the number of shares based on the closing price at the previous day of the board meeting resolution.

(17) Employee share-based payment

A. For the equity-settled share-based payment arrangements, the employee services received are measured at the fair value of the equity instruments granted at the grant date, and are recognised as compensation cost over the vesting period, with a corresponding adjustment to equity. The fair value of the equity instruments granted shall reflect the impact of market vesting conditions and non-market vesting conditions. Compensation cost is subject to adjustment based on the service conditions that are expected to be satisfied and the estimates of the number of equity instruments that are expected to vest under the non-market vesting conditions at each balance sheet date. Ultimately, the amount of compensation cost recognised is based on the number of equity instruments that eventually vest.

B. The grant date of the share-based payment arrangements is the date that the subscription price and shares are determined.

(18) Income tax

A. The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or items recognised directly in equity, in which cases the tax is recognised in other comprehensive income or equity.

B. The current income tax expense is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions where appropriate based on the amounts expected to be paid to the tax authorities. An additional tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the stockholders resolve to retain the earnings.

C. Deferred tax is recognised, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the parent company only balance sheet. However, the deferred tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences. Deferred tax is provided on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable

-21-

future. Deferred tax is determined using tax rates and laws that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled.

D. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised. At each balance sheet date, unrecognised and recognised deferred tax assets are reassessed.

E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realise the asset and settle the liability simultaneously.

(19) Dividends

Dividends are recorded in the Company’s financial statements in the period in which they are approved by the Board of Directors. Cash dividends are recorded as liabilities; stock dividends are recorded as stock dividends to be distributed in the Company’s financial statements in the period in which they are resolved by the Company’s shareholders and are reclassified to ordinary shares on the effective date of new shares issuance.

(20) Revenue recognition

A. Investment revenue

The Company recognises share of profit or loss of subsidiaries and associates generated after acquisition in revenue or cost.

B. Sales of services

(a) The Company provided administrative resources and management services to subsidiaries, and the revenue will have to be recognised based on the stage of completion at the balance sheet date.

(b) If the outcome of providing services cannot be estimated reliably, revenue is recognised only to the extent that costs incurred are likely to be recoverable. If the incurred costs are likely to be recovered, revenue is recognised to the extent that costs incurred are likely to be recoverable; if the incurred costs are not likely to be recovered, revenue shall not be recognised, and the incurred costs shall be recognised in expenses.

CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

The preparation of these parent company only financial statements requires management to make critical judgements in applying the Company’s accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions

-22-

and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. The related information is addressed below:

(1) Critical judgements in applying the Company’s accounting policies

Except for the accounting estimations (detailed in (2) below), the management does not make any judgement that significant affect the recognised amounts in parent company only financial statements when applying the Company’s accounting polices.

(2) Critical accounting estimates and assumptions

The Company makes accounting estimates in applying reasonable expectation concerning future events. However, assumptions and estimates may differ from the actual results. Such assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year; and the related information is addressed below: Impairment assessment of investments accounted for using equity method

The Company assesses the impairment of an investment accounted for using equity method as soon as there is any indication that it might have been impaired and its carrying amount cannot be recovered. The Company assesses the recoverable amount of an investment accounted for under the equity method based on the present value of the Company’s share of expected future cash flows of the investee, and analyses the reasonableness of related assumptions.

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) Cash and cash equivalents

	December 31, 2025	December 31, 2024
Cash on hold	$ 88	$ 88
Checking accounts and demand deposits	267,508	156,156
	$ 267,596	$ 156,244

A. The Company transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.
B. The Company has no cash and deposits pledged to others.

(2) Financial assets and liabilities at fair value through profit or loss

Items	December 31, 2025	December 31, 2024
Current items:
Financial assets mandatorily measured at fair value through profit or loss
Listed stocks	$ 21,555	$ 61,467
Non-hedging derivatives (Redemption rights to the fourth domestic issuance of secured convertible corporate bonds)	-	896
Valuation adjustment	( 5,559)	( 12,694)
	$ 15,996	$ 49,669

-24-

Items	December 31, 2025	December 31, 2024
Non-current items:
Financial assets mandatorily measured at fair value through profit or loss
Privately offered funds
Non-hedging derivatives	$ 45,000	$ 10,500
Valuation adjustment	( 1,357)	( 1,419)
	$ 43,643	$ 9,081
Financial liabilities held for trading
Privately offered funds
(Redemption rights to the fifth domestic issuance of secured convertible corporate bonds)	($ 11,340)	$ -

For the years ended December 31, 2025 and 2024, net gain (loss) on financial assets at fair value through profit or loss was ($4,449) and $4,030, respectively, shown as ‘other gains and losses’.

(3) Financial assets at fair value through other comprehensive income

Items	December 31, 2025	December 31, 2024
Non-current items:
Listed stocks	$ 340,215	$ 340,215
Valuation adjustment	( 325,702)	( 327,491)
	$ 14,513	$ 12,724

A. The Company has elected to classify equity investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments amounted to $14,513 and $12,724 as at December 31, 2025 and 2024, respectively.

B. The Company recognised $1,789 and $2,565 in other comprehensive income (loss) for fair value change for the years ended December 31, 2025 and 2024, respectively.

(4) Investments accounted for using equity method

	December 31, 2025	December 31, 2024
Chiu Ho Medical System Co., Ltd.	$ 4,898,741	$ 4,835,997
Tomorrow Medical System Co., Ltd.	975,953	1,021,266
Chiu Ho Scientific Co., Ltd.	150,089	147,976
Chiu Ho Biotech Co., Ltd.	95,858	237,614
Shin-Ho Biotech Co., Ltd.	273,661	69,598
Tong-Lin Instruments Co., Ltd.	380,688	384,134
Hua Lin Instruments Co., Ltd.	400,824	391,750
E Century Healthcare Corporation	659,580	644,782
CHC Healthcare (BVI) Limited	302,399	358,517
Treasure of Health Co., Ltd.	457,155	415,228
CHC Healthcare (UK) Limited	6,737	1,562
	$ 8,601,685	$ 8,508,424

Details of the Company's subsidiaries are provided in Note 4(3) of the Company's consolidated financial statements as of and for the year ended December 31, 2025.

(5) Leasing arrangements-lessee

A. The Company leases buildings from subsidiary, Chiu Ho Medical System Co., Ltd. Rental contracts are typically made for periods of 5 years. Rents are paid at the beginning of the month. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose covenants, but leased assets may not be used as security for borrowing purposes.

B. The carrying amount of right-of-use assets and the depreciation charge are as follows:

| | December 31, 2025
Book value | December 31, 2024
Book value |
| --- | --- | --- |
| Buildings | $ 16,633 | $ 23,516 |
| | Year ended December 31, | |
| | 2025 | 2024 |
| | Depreciation charge | Depreciation charge |
| Buildings | $ 6,883 | $ 6,883 |

C. For the years ended December 31, 2025 and 2024, the Company had no additions to right-of-use assets.

D. The information on profit and loss accounts relating to lease contracts is as follows:

	Year ended December 31,
	2025	2024
Items affecting profit or loss
Interest expense on lease liabilities	$ 372	$ 498

E. For the years ended December 31, 2025 and 2024, the Company's total cash outflow for leases was $7,200 for both years.

(6) Short-term borrowings

Type of borrowings	December 31, 2025	December 31, 2024
Bank borrowings
Unsecured borrowings	$ 200,000	$ 250,000
Interest rate	1.920%~1.925%	1.925%~1.950%

For the years ended December 31, 2025 and 2024, the Company has no asset pledged as collateral for short-term borrowings.

-25-

-26-

(7) Bonds payable

	December 31, 2025	December 31, 2024
Bonds payable	$ 900,000	$ 1,311,910
Less: Discount on bonds payable	( 96,490)	( 5,403)
	803,510	1,306,507
Less: Current portion or exercise of put options (shown as “long-term liabilities, current portion”)	-	( 1,306,507)
	$ 803,510	$ -

A. Fourth domestic secured convertible bonds issued by the Company

(a) The terms of the fourth domestic secured convertible bonds issued by the Company are as follows:

i. Convertible bonds totaling $1,515,000 with zero coupon rate which were issued at a 101% premium of the total face value of $1,500,000 as approved by the regulatory authority. The bonds mature five years from the issue date (August 4, 2020 ~ August 4, 2025) and will be redeemed in cash at 102.525% of face value at the maturity date. The bonds were listed on the Taipei Exchange on August 4, 2020.

ii. The bondholders have the right to request TDCC through the security dealers for conversion of the bonds into common shares of the Company during the period from the date after three month of the bonds issue to the maturity date, except for the stop transfer period as specified in the terms of the bonds or the laws/regulations. The rights and obligations of the new shares converted from the bonds are the same as the issued and outstanding common shares.

iii. The conversion price of the bonds is set up based on the pricing model in the terms of the bonds, and is subject to adjustments if the condition of the anti-dilution provisions occurs subsequently. The conversion price on the issue date is NT$53.9 (in dollars). On July 2, 2025, July 16, 2024, July 18, 2023, July 19, 2022, November 29, 2021 and August 3, 2021, the Company adjusted the conversion price per share to NT$43.9, NT$45.2, NT$46.9, NT$48.4, NT$50.9 and NT$51.0 (in dollars), respectively, according to the rules described above.

iv. The Company may repurchase all the bonds outstanding in cash at the bonds' face value at any time after the following events occur: (i) the closing price of the Company's common shares is above the then conversion price by 30% for 30 consecutive trading days during the period from the date after three months of the bonds issue to 40 days before the maturity date, or (ii) the outstanding balance of the bonds is less than 10% of total initial issue amount during the period from the date after one month of the bonds issue to 40 days before the maturity date.

v. Under the terms of the bonds, all bonds redeemed (including bonds repurchased from the Taipei Exchange), matured and converted are retired and not to be re-issued; all rights

and obligations attached to the bonds are also extinguished.

(b) The convertible bonds matured on August 4, 2025. Part of the bonds were converted into 33,033 thousand shares of common stock, and the remaining unconverted bonds were redeemed at $7,484 by cash. The Company transferred the forfeited stock options of $123 to capital surplus-forfeited stock options (shown as capital surplus-others).

B. Fifth domestic secured convertible bonds issued by the Company

(a) The terms of the fifth domestic secured convertible bonds issued by the Company are as follows:

i. Convertible bonds totaling $900,000 with zero coupon rate which were issued at a 100.5% premium of the total face value of $904,500 as approved by the regulatory authority. The bonds mature five years from the issue date (June 20, 2025 ~ June 20, 2030) and will be redeemed in cash at face value at the maturity date. The bonds were listed on the Taipei Exchange on June 20, 2025.

ii. The bondholders have the right to request TDCC through the security dealers for conversion of the bonds into common shares of the Company during the period from the date after three months of the bonds issue to the maturity date, except for the stop transfer period as specified in the terms of the bonds or the laws/regulations. The rights and obligations of the new shares converted from the bonds are the same as the issued and outstanding common shares.

iii. The conversion price of the bonds is set up based on the pricing model in the terms of the bonds, and is subject to adjustments if the condition of the anti-dilution provisions occurs subsequently. The conversion price on the issue date is NT$48.4 (in dollars). On July 2, 2025, the Company adjusted the conversion price per share to NT$47.0 (in dollars), respectively, according to the rules described above.

v. The bondholders have the right to require the Company to redeem any bonds at the price of the bonds' face value plus 0.752% of the face value as interest refund upon three years from the issue date.

vi. Under the terms of the bonds, all bonds redeemed (including bonds repurchased from the Taipei Exchange), matured and converted are retired and not to be re-issued; all rights and obligations attached to the bonds are also extinguished.

-27-

(b) Regarding the fifth issuance of secured convertible bonds, the equity conversion options amounting to $100,170 were separated from the liability component and were recognised in ‘capital surplus - others’ in accordance with IAS 32 as of December 31, 2025. The put options and call options embedded in bonds payable were separated from their host contracts and were recognised in ‘financial assets or liabilities at fair value through profit or loss’ in net amount in accordance with IFRS 9 because the economic characteristics and risks of the embedded derivatives were not closely related to those of the host contracts. As of December 31, 2025, the effective interest rate of the bonds payable after such separation was 2.5704%

C. There were no assets pledged as collateral for the fourth and fifth domestic bonds.

(8) Long-term borrowings

Type of borrowings	Borrowing period	December 31, 2025	December 31, 2024
Bank borrowings
Secured borrowings	2022.10~2027.10	$ 1,404,200	$ 1,352,000
Less: Current portion		( 247,800)	-
		$ 1,156,400	$ 1,352,000
Interest rate range		2.38%	2.34%~2.35%

A. On September 21, 2022, the Company and its subsidiary, Tomorrow Medical System Co., Ltd., signed a syndicated loan agreement in the amount of $2,580,000 with syndicate of banks including First Commercial Bank, in order to repay the Group’s existing financial liabilities and increase the working capital. In accordance with the syndicated loan agreement, the loan can be redrawn within the contract period. For each drawdown, the term shall not exceed 6 months and the amount of drawdown shall not be less than 50 million. For the amount that has not been paid at maturity, there is no need for the part of the same amount to make an additional procedure of remittance and loan. Therefore, the aforementioned financing will be listed as long-term borrowings and agreed to the following terms:

(a) All the credit amounts which obtained according to the contract shall be used for the credit purposes specified in the contract.

(b) The Company will periodically submit a financial assurance letter to the banks, indicating whether the Company has achieved the required financial ratios based on the annual and semi-annual consolidated financial statements as follows:

i. Current ratio must be 100% or higher.
ii. Debt ratio must be equal to or less than 170%.
iii. Interest coverage ratio must be 3 or higher.
iv. Tangible net assets must be $4,000,000 or higher.

If the Company fails to meet any of the requirements stated above, remedial measures, such as capital increase, must be taken to address the issue before the financial reporting date of the next annual or half-year consolidated financial statements. If the issue is resolved with the remedial measures, it is not considered a breach of contract. However, the Company is required to pay a fee, equal to 0.1% of the unpaid principal balance on the audit date, to the

-28-

agency bank, who will maintain distribute this fee among the syndicate lenders.

(c) The Company shall maintain directly/ indirectly a 100% equity interest in Chiu Ho Medical System Co., Ltd., Tomorrow Medical System Co., Ltd., and Hsing-Yeh Biotenology Co., Ltd. and the control over those companies' operations.

If the Company fails to meet this requirement, First Commercial Bank will determine whether there has been a breach of contract and, if necessary, call a meeting with all the syndicate lenders to discuss the matter.

B. Information on assets pledged as collateral for long-term borrowings is provided in Note 7(3)E.

(9) Pensions

A. The Company has established a defined contribution pension plan (the "New Plan") under the Labor Pension Act (the "Act"), covering all regular employees with R.O.C. nationality. Under the New Plan, the Company contributes monthly an amount based on 6% of the employees' monthly salaries and wages to the employees' individual pension accounts at the Bureau of Labor Insurance. The benefits accrued are paid monthly or in lump sum upon termination of employment.

B. The pension costs under the defined contribution pension plan of the Company for the years ended December 31, 2025 and 2024 were $2,531 and $2,431, respectively.

(10) Share-based payment

A. As of December 31, 2025 and 2024, the Company's share-based payment transactions are as follows:

Type of arrangement	Grant date	Quantity granted (in thousands of shares)	Contract period	Vesting conditions
Employee stock options-106	2018.4.13	2,000 (Note 2)	7 years	(Note 1)

Note 1: After two years from the grant date, employees are allowed to exercise their stock options according to the vesting schedule and proportion specified in the plan.

Note 2: 1,262 thousand shares of which were granted to the employees of subsidiaries and second-tier subsidiaries.

B. Details of the share-based payment arrangements are as follows:

Stock options	2025		2024
	No. of options (in thousands of shares)	Weighted-average exercise price (in dollars)	No. of options (in thousands of shares)	Weighted-average exercise price (in dollars)
Options outstanding at January 1	142	$ 25.50	172	$ 26.50
Options forfeited	( 120)	25.50	-	-
Options exercised	( 22)	25.50	( 30)	25.83
Options outstanding at December 31	-	-	142	25.50
Options exercisable at December 31	-		142

C. As of December 31, 2025 and 2024, number of options outstanding granted to the employees of subsidiaries and second-tier subsidiaries were 0 shares and 114 thousand shares, respectively, and number of options exercisable were 0 shares and 114 thousand shares, respectively.

D. For the years ended December 31, 2025 and 2024, the weighted-average stock price of stock options on exercise dates were NT$48.66 and NT$47.30 (in dollars), respectively.

E. The expiry date and exercise price of stock options outstanding at the balance sheet date are as follows:

Issue date approved	Expiry date	December 31, 2025		December 31, 2024
		No. of shares (in thousands of shares)	Exercise price (in dollars)	No. of shares (in thousands of shares)	Exercise price (in dollars)
2018.4.13	2025.4.12	-	$ -	142	$ 25.50

F. The Black-scholes option-pricing model was used for valuation of fair value of the stock options granted. The related information is listed as follows:

Type of arrangement	Grant date	Stock price (in dollars)	Exercise price (in dollars)	Expected price volatility	Expected option life	Expected dividends	Risk-free interest rate	Fair value per unit (in dollars)
Employee stock options-106	2018.4.13	$ 34.50	$ 34.5	30.02%	5.25 years	0%	0.75%	$8.46~$10.91

G. For the years ended December 31, 2025 and 2024, expenses incurred on the Company's share-based payment transactions.

H. On July 16, 2024, July 18, 2023, July 19, 2022, November 29, 2021 and August 3, 2021, the exercise prices of employee stock options-106 were adjusted to NT$25.5, NT$26.5, NT$27.4, NT$28.8 and NT$28.8 (in dollars), respectively.

(11) Share capital

A. As of December 31, 2025, the Company's authorised capital was $2,500,000, consisting of 250 million shares of ordinary stock, and the paid-in capital was $1,953,110 with a par value of $10 (in dollars) per share. All proceeds from shares issued have been collected.

Movements in the number of the Company's ordinary shares outstanding are as follows:

	(In thousands of shares)
	2025	2024
At January 1	166,865	166,419
Employee stock options exercised	22	30
Conversion of convertible bonds	28,424	416
At December 31	195,311	166,865

B. To attract strategic investors, strengthen the Company's financial structure, enrich working capital and improve the benefits of future competitiveness, the stockholders at their annual stockholders' meeting on July 1, 2021 adopted a resolution to raise additional cash through

private placement. The maximum number of shares to be issued through the private placement is 20,000 thousand shares. The capital increase shall be processed in installments (no more than three times) within one year from the date of the resolution of the stockholders' meeting. The stockholders authorised the Board of Directors to determine the actual pricing date and issuance price within the range of not less than the percentage of the resolution of the stockholders' meeting considering the situation of the specific person and the market in the future. As resolved by the Board of Directors on October 6, 2021, the first effective date was on October 13, 2021, and the number of shares issued was 4,722 thousand shares at the subscription price of $35.1 (in dollars) per share. The amount of capital raised through the private placement was $165,742 which had been registered. Pursuant to the Securities and Exchange Act, the ordinary shares raised through the private placement are subject to certain transfer restrictions and cannot be listed on the stock exchange until three years after they have been issued and have been offered publicly. Other than these restrictions, the rights and obligations of the ordinary shares raised through the private placement are the same as other issued ordinary shares.

(12) Capital surplus

A. Pursuant to Paragraph 4, Article 31 of the Business Mergers and Acquisitions Act, if a company becomes a wholly-owned subsidiary of another company through a share exchange, its undistributed earnings become part of the capital surplus of the acquiring company (parent company). Therefore, if the increase in the investment holding company's capital surplus is from the undistributed earnings of the subsidiary before the share exchange, this amount can be distributed as cash dividends or capitalised. Moreover, the proportion that can be capitalised is not subject to the restrictions set forth in Article 8 of the Securities and Exchange Act Enforcement Rules. In addition, according to Tai-Cai-Rong-Yi-Zi No. 0910016280, such increase in capital surplus was not generated by the holding company's business operations and thus will not affect the remuneration of directors and supervisors and bonuses of employees. As of December 31, 2025, capital surplus that is attributable to the undistributed earnings of Chiu Ho Medical System Co., Ltd. and other associates before share exchanges amounted to $44,390.

B. Pursuant to the R.O.C. Company Act, capital surplus arising from paid-in capital in excess of par value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. However, capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.

C. Please refer to Note 6(10) for information on capital surplus - employee stock options.

-31-

(13) Retained earnings

A. Under the Company’s Articles of Incorporation, the current year’s earnings, if any, shall first be used to pay all taxes and offset prior years’ operating losses and then 10% of the remaining amount shall be set aside as legal reserve unless legal reserve equals the authorised share capital. Special reserve is then appropriated or reversed in accordance with related regulations. At least 50% of the remainder, if any, and accumulated undistributed earnings from prior years shall be proposed by the Board of Directors for appropriation. The proposal for the appropriation of earnings shall be approved by the shareholders if dividends are distributed by issuing new shares and shall be reported to the shareholders during their meeting after being specially resolved by the Board of Directors if dividends are distributed in the form of cash.

B. Except for covering accumulated deficit or issuing new stocks or cash to shareholders in proportion to their share ownership, the legal reserve shall not be used for any other purpose. The use of legal reserve for the issuance of stocks or cash to shareholders in proportion to their share ownership is permitted, provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company’s paid-in capital.

C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.

D. The proposal on 2024 and 2023 earnings appropriations which were resolved at the shareholders’ meeting on June 4, 2025 and June 12, 2024, respectively, are as follows:

	Years ended December 31,
	2024		2023
	Amount	Dividends per share (in dollars)	Amount	Dividends per share (in dollars)
Legal reserve	$ 16,829		$ 41,887
Appropriation for (reversal of) special reserve	9,477		( 1,760)
Cash dividends	251,967	$ 1.51	334,502	$ 2.01
	$ 278,273		$ 374,629

The aforementioned earnings appropriations for the years ended December 31, 2024 and 2023 were in agreement with the amounts resolved by the Board of Directors during its meetings held on March 12, 2025 and March 13, 2024, respectively, and the ex-dividend dates resolved in the same meetings were July 2, 2025 and July 16, 2024, respectively. For more information on the aforementioned earnings appropriations proposed by the Board of Directors and resolved by the shareholders, please go to the Market Observation Post System website maintained by the Taiwan Stock Exchange.

E. The appropriations for 2025 earnings as resolved by the Board of Directors on March 10, 2026 are as follows:

	Year ended December 31, 2025
	Amount	Dividends per share (in dollars)
Legal reserve	$ 18,628
Appropriation for special reserve	18,202
Cash dividends	214,842	$ 1.10
	$ 251,672

(14) Operating revenue

	Years ended December 31,
	2025	2024
Investment revenue	$ 203,090	$ 194,764
Revenue from customer contracts
Timing of revenue recognition-over time
- internal customers - management service revenue	141,460	139,390
	$ 344,550	$ 334,154

(15) Interest income

	Years ended December 31,
	2025	2024
Interest income from bank deposits	$ 2,636	$ 1,169
Interest income from loans to related parties	11,653	7,868
	$ 14,289	$ 9,037

(16) Other income

	Years ended December 31,
	2025	2024
Dividend income	$ 10	$ 330
Other income	12	9
	$ 22	$ 339

(17) Other gains and losses

	Years ended December 31,
	2025	2024
Net currency exchange gains	$ -	$ 2
Net (losses) gains on financial assets and liabilities at fair value through profit or loss	(4,449)	4,030
Other losses	-	-
	($ 4,449)	$ 4,032

(18) Finance costs

	Years ended December 31,
	2025	2024
Interest expense:
Bank borrowings	$ 36,794	$ 34,664
Convertible bonds	15,007	9,235
Lease liability	372	498
Financial expense, others	5,499	10,762
	$ 57,672	$ 55,159

(19) Expenses by nature

	Years ended December 31,
	2025		2024
	Operating Cost	Operating Expense	Operating Cost	Operating Expense
Employee benefit expense
Wages and salaries	$ 71,855	$ -	$ 81,537	$ -
Labour and health insurance fees	6,023	-	5,774	-
Pension costs	2,531	-	2,431	-
Directors’ remuneration	6,516	-	6,259	-
Other personnel expenses	2,392	-	2,361	-
Depreciation charge	7,208	-	7,206	-
Amortisation charge	213	-	197	-
	$ 96,738	$ -	$ 105,765	$ -

A. In accordance with the Articles of Incorporation of the Company, a ratio of distributable profit of the current year (i.e. profit before tax less profit margin before the appropriation of employees’ compensation and directors’ remuneration), after covering accumulated losses, shall be distributed as employees’ compensation and directors’ remuneration. The ratio shall not be lower than 0.05% for employees’ compensation and shall not be higher than 5% for directors’ remuneration. Additionally, on June 4, 2025, the Company's Annual General Meeting of Shareholders approved certain amendments to the Articles of Incorporation. These amendments stipulate that, of the total employees’ compensation, not less than 20% shall be allocated as compensation to non-managerial employees.

The aforementioned employees’ compensation and directors’ remuneration requires the approval from the majority of the directors attending a board meeting, with more than two thirds of all directors in attendance, and must be reported to the shareholders.

Employees’ compensation is distributed in the form of shares or cash, and the recipients may include employees of affiliates who meet certain conditions. The distribution plan is set by the Chairman.

B. For the years ended December 31, 2025 and 2024, employees' compensation was accrued at $115 and $150, respectively; directors' remuneration was accrued at $5,600 for both years. The aforementioned amounts were recognised in salary expenses.

Employees' compensation of $150 and directors' remuneration of $5,600 for 2024 as resolved by the Board of Directors were in agreement with those amounts recognised in the 2024 financial statements.

Information about employees' compensation and directors' remuneration of the Company as resolved at the meeting of Board of Directors and approved by shareholders at their meeting will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(20) Income tax

A. Income tax expense

(a) Components of income tax expense:

	Years ended December 31,
	2025	2024
Current tax:
Current tax on profits for the year	$ -	$ -
Tax on undistributed surplus earnings	-	2,212
Prior year income tax overestimation	( 2)	( 234)
Total current tax	( 2)	1,978
Deferred tax
Origination and reversal of temporary differences	1,584	9
Income tax expense	$ 1,582	$ 1,987

(b) Reconciliation between income tax benefit and accounting profit:

	Years ended December 31,
	2025	2024
Income tax calculated based on profit before tax and statutory tax rate	$ 37,572	$ 34,074
Expenses disallowed by tax regulation	3,562	3,909
Tax exempt income by tax regulation	( 47,184)	( 45,166)
Temporary differences not recognised as deferred tax assets	7,634	4,117
Taxable losses not recognised as deferred tax assets	-	3,075
Tax on undistributed surplus earnings	-	2,212
Prior year income tax overestimation	( 2)	( 234)
Income tax expense	$ 1,582	$ 1,987

B. Amounts of deferred tax assets or liabilities as a result of temporary differences and tax losses are as follows:

	2025
	January 1	Recognised in profit or loss	Recognised in other comprehensive income	December 31
Temporary differences
- Deferred tax assets:
Unused compensated absences	$ 134	($ 26)	$ -	$ 108
Income tax losses	58,482	( 1,558)	-	56,924
	58,616	( 1,584)	-	57,032
Temporary differences
- Deferred tax liabilities:
Effects of business combination	( 734)	-	-	( 734)
	$ 57,882	($ 1,584)	$ -	$ 56,298
	2024
	January 1	Recognised in profit or loss	Recognised in other comprehensive income	December 31
Temporary differences
- Deferred tax assets:
Unused compensated absences	$ 143	($ 9)	$ -	$ 134
Income tax losses	58,482	-	-	58,482
	58,625	( 9)	-	58,616
Temporary differences
- Deferred tax liabilities:
Effects of business combination	( 734)	-	-	( 734)
	$ 57,891	($ 9)	$ -	$ 57,882

C. Expiration dates of unused tax losses and amounts of unrecognised deferred tax assets are as follows:

December 31, 2025
Year incurred	Amount filed/assessed	Unused amount	Unrecognised deferred tax assets	Expiry year
2018	$ 309,790	$ 284,617	$ -	2028
December 31, 2024
Year incurred	Amount filed/assessed	Unused amount	Unrecognised deferred tax assets	Expiry year
2018	$ 309,790	$ 292,410	$ -	2028

D. The amounts of deductible temporary differences that were not recognised as deferred tax assets are as follows:

	December 31, 2025	December 31, 2024
Deductible temporary differences	$ 193,783	$ 153,308

E. The Company’s income tax returns through 2023 have been assessed and approved by the Tax Authority.

(21) Earnings per share

	Year ended December 31, 2025
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
Basic earnings per share
Profit attributable to ordinary shareholders of the parent	$ 186,277	185,811	$ 1.00
Diluted earnings per share
Profit attributable to ordinary shareholders of the parent	$ 186,277	185,811
Assumed conversion of all dilutive potential ordinary shares
Employee stock options	-	22
Employees’ compensation	-	4
Convertible bonds	8,456	9,443
Profit attributable to ordinary shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	$ 194,733	195,280	$ 1.00

-38-

	Year ended December 31, 2024
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
Basic earnings per share
Profit attributable to ordinary shareholders of the parent	$ 168,384	166,769	$ 1.01
Diluted earnings per share
Profit attributable to ordinary shareholders of the parent	$ 168,384	166,769
Assumed conversion of all dilutive potential ordinary shares
Employee stock options	-	80
Employees’ compensation	-	4
Convertible bonds	22,571	27,789
Profit attributable to ordinary shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	$ 190,955	194,642	$ 0.98

Because employees' compensation may be distributed in the form of shares, the calculation of diluted earnings per share assumes that employees' compensation would be distributed entirely in shares. These dilutive potential common shares are included in the weighted average number of outstanding shares when calculating diluted earnings per share. When calculating basic earnings per share, shares issued as part of employees' compensation are included in the weighted average number of outstanding shares only if the number of such shares have been confirmed and resolved by the shareholders. Shares issued as part of employees' compensation are not considered bonus shares, therefore no retrospective adjustment is applied when calculating basic and diluted earnings per share.

(22) Changes in liabilities from financing activities

	Short-term borrowings	Bonds payable	Long-term borrowings	Lease liability	Total liabilities from financing activities
January 1, 2025	$ 250,000	$ 1,306,507	$ 1,352,000	$ 23,859	$ 2,932,366
Changes in cash flow from financing activities	( 50,000)	891,721	52,200	( 6,828)	887,093
Changes in other non-cash items	-	( 1,394,718)	-	-	( 1,394,718)
December 31, 2025	$ 200,000	$ 803,510	$ 1,404,200	$ 17,031	$ 2,424,741

-39-

	Short-term borrowings	Bonds payable	Long-term borrowings	Lease liability	Total liabilities from financing activities
January 1, 2024	$ 100,000	$ 1,317,066	$ 1,352,000	$ 30,561	$ 2,799,627
Changes in cash flow from financing activities	150,000	-	-	( 6,702)	( 143,298)
Changes in other non-cash items	-	( 10,559)	-	-	( 10,559)
December 31, 2024	$ 250,000	$ 1,306,507	$ 1,352,000	$ 23,859	$ 2,932,366

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

The Company’s stocks are held by the public, so it has neither an ultimate parent company nor ultimate controlling party.

(2) Names of related parties and relationship

Names of related parties	Relationship with the Company
Chiu Ho Medical System Co., Ltd.	Subsidiary
Tomorrow Medical System Co., Ltd.	Subsidiary
Chiu Ho Scientific Co., Ltd.	Subsidiary
Chiu Ho Biotech Co., Ltd.	Subsidiary
Shin-Ho Biotech Co., Ltd.	Subsidiary
Tong-Lin Instruments Co., Ltd.	Subsidiary
Hua Lin Instruments Co., Ltd.	Subsidiary
E Century Healthcare Corporation	Subsidiary
Hsing-Yeh Biotechnology Co., Ltd.	Subsidiary
SenCare Healthcare Company	Subsidiary
Treasure of Health Co., Ltd.	Subsidiary
CHC Healthcare (UK) Limited (CHC (UK))
CHC Long-Term Care Corporation	Subsidiary

(3) Significant transactions and balances with related parties

A. Management service revenues (shown as ‘Operating revenue’)

	Years ended December 31,
	2025	2024
Sales of services
Chiu Ho Medical System Co., Ltd.	$ 66,000	$ 68,400
Tomorrow Medical System Co., Ltd.	14,520	15,600
Chiu Ho Scientific Co., Ltd.	7,560	7,080
Tong-Lin Instruments Co., Ltd.	6,180	7,980
Hua Lin Instruments Co., Ltd.	9,780	8,940
E Century Healthcare Corporation	14,940	13,140
Hsing-Yeh Biotechnology Co., Ltd.	13,200	9,960
Others	9,280	8,290
	$ 141,460	$ 139,390

Management service revenue pertains to revenue arising from administrative resources, technical consultation on medical practices and management services rendered by the Company to related parties and the prices and payment terms are decided by both parties.

B. Other receivables due from related parties

Loans to related parties (including interest receivable)

	Year ended December 31, 2025
	Maximum balance	Ending balance	Interest rate	Amount of interest	Ending balance of interest receivable
Shin-Ho Biotech Co., Ltd.	$ 390,000	$ 250,000	2%~3.5%	$ 5,685	$ 1,609
Tomorrow Medical System Co., Ltd.	200,000	200,000	2%~3.5%	973	973
Hsing-Yeh Biotechnology Co., Ltd.	400,000	400,000	2%~3.5%	740	740
Treasure of Health Co., Ltd.	160,000	110,000	2%~3.5%	2,531	570
Others	100,000	100,000	2%~3.5%	1,724	1,304
		$1,060,000		$ 11,653	$ 5,196
	Year ended December 31, 2024
---	---	---	---	---	---
	Maximum balance	Ending balance	Interest rate	Amount of interest	Ending balance of interest receivable
Shin-Ho Biotech Co., Ltd.	$ 320,000	$ 320,000	2%~3.5%	$ 5,455	$ 4,978
Treasure of Health Co., Ltd.	150,000	60,000	2%~3.5%	1,860	581
Others	50,000	50,000	2%~3.5%	553	553
		$ 430,000		$ 7,868	$ 6,112

The loans lent to subsidiaries are repayable within 1 year.

C. Lease transactions—lessee

(a) The Company leases offices from related parties. Rental contracts are all typically made for periods of 5 years. Rents are determined according to the market price and paid monthly.

(b) Lease liabilities

Chiu Ho Medical System Co., Ltd.
December 31, 2025 December 31, 2024
$ 17,031 $ 23,859

D. Others

(a) Capital increase of subsidiaries

Company name	Year ended December 31, 2025
	Capital increase price per share (in dollars)	Total transaction amount	Percentage of ownership before capital increase	Percentage of ownership after capital increase
Shin-Ho Biotech Co., Ltd.	$ 10	$ 280,000	100%	100%
Treasure of Health Co., Ltd.	88	16,830	51%	50%
CHC (UK)	40.272	7,249	100%	100%
		$ 304,079
Company name	Year ended December 31, 2024
---	---	---	---	---
	Capital increase price per share (in dollars)	Total transaction amount	Percentage of ownership before capital increase	Percentage of ownership after capital increase
Treasure of Health Co., Ltd.	$ 110	$ 71,247	51%	51%

(b) Proceeds from capital reduction of subsidiaries

Company name	Year ended December 31, 2025		Year ended December 31, 2024
	Percentage of capital reduction	Total transaction amount	Percentage of capital reduction	Total transaction amount
Hua Lin Instruments Co., Ltd.	-	$ -	15.73%	$ 56,000
Chiu Ho Biotech Co., Ltd.	69.95%	139,640	16.69%	40,000
Tong-Lin Instruments Co., Ltd.	-	-	11.43%	40,000
		$ 139,640		$ 136,000

(c) Inter-company collections of consolidated tax returns on behalf of others/ Income tax returns paid on behalf of others

	December 31, 2025
	Other receivables-related parties	Other receivables-related parties
Chiu Ho Medical System Co., Ltd.	$ 25,048	$ -
Tomorrow Medical System Co., Ltd.	-	2,013
Chiu Ho Scientific Co., Ltd.	1,429	-
Chiu Ho Biotech Co., Ltd.	8,831	-
Shin-Ho Biotech Co., Ltd.	-	19,133
Tong-Lin Instruments Co., Ltd.	628	-
Hua Lin Instruments Co., Ltd.	3,869	-
	$ 39,805	$ 21,146

December 31, 2024: None.

E. Endorsements and guarantees provided to related parties

(a) As of December 31, 2025 and 2024, the balances of financial guarantees provided by the Company to other subsidiaries as collateral for bank borrowings are as follows.

	December 31, 2025	December 31, 2024
Chiu Ho Medical System Co., Ltd.	$ 400,000	$ 850,000
Tomorrow Medical System Co., Ltd.	988,800	1,288,000
Others	884,720	851,000
	$ 2,273,520	$ 2,989,000

(b) As of December 31, 2025 and 2024, the Company and its subsidiary, Tomorrow Medical System Co., Ltd., signed a syndicated loan agreement with First Commercial Bank, and the total syndicated loan amounted to $2,580,000 for both years. This syndicated loan is jointly guaranteed by the Company and the Company's chairman, Mr. Pei-Lin Lee, and pledged the land and buildings of the subsidiaries, Chiu Ho Medical System Co., Ltd. as collateral.

(4) Key management compensation

	Years ended December 31,
	2025	2024
Salaries and other short-term employee benefits	$ 31,874	$ 36,794
Post-employment benefits	324	324
	$ 32,198	$ 37,118

PLEDGED ASSETS

None.

SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

(1) Contingencies

None.

(2) Commitments

A. For material commitments related to the Company's syndicated bank loan facility, please refer to Note 6(8).

B. For material commitments to and endorsements and guarantees for related parties, please refer to Note 7(3)5.

C. As of December 31, 2025 and 2024, the Company's uncalled capital commitments under signed private equity fund agreements amounted to $45,000 and $19,500, respectively.

SIGNIFICANT DISASTER LOSS

None.

SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

On January 8, 2026, the Company’s subsidiary, Chiu Ho Medical System Co., Ltd., entered into an agreement with MacKay Memorial Hospital for the sale of a proton therapy system, which will benefit the hospital’s business expansion and sales.

OTHERS

(1) Capital management

The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

(2) Financial instruments

A. Financial instruments by category

	December 31, 2025	December 31, 2024
Financial assets
Financial assets at fair value through profit or loss
Financial assets mandatorily measured at fair value through profit or loss	$ 59,639	$ 58,750
Financial assets at fair value through other comprehensive income
Designation of equity instrument	$ 14,513	$ 12,724
Financial assets at amortised cost
Cash and cash equivalents	$ 267,596	$ 156,244
Other receivables (including related parties)	1,105,001	436,112
	$ 1,372,597	$ 592,356

-44-

Financial liabilities	December 31, 2025	December 31, 2024
Financial liabilities at amortised cost
Short-term borrowings	$ 200,000	$ 250,000
Notes payable	135	135
Other payables	39,686	22,097
Bonds payable	803,510	1,306,507
Long-term borrowings	1,404,200	1,352,000
	$ 2,447,531	$ 2,930,739
Lease liability	$ 17,031	$ 23,859

B. Financial risk management policies

(a) The Company’s operating activities expose it to a variety of financial risks, including market risk (including foreign exchange risk, interest rate risk and price risk), credit risk and liquidity risk. The Company’s overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Company’s financial position and financial performance.

(b) Risk management is carried out by the Company treasury department under policies approved by the Board of Directors. The Company treasury identifies, evaluates and hedges financial risks in close cooperation with the Company’s operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as credit risk.

C. Significant financial risks and degrees of financial risks

(a) Market risk

Foreign exchange risk

i. The Company conducts business worldwide and imports state-of-the-art medical equipment and supplies from various countries and is therefore exposed to foreign exchange risk from multiple foreign currencies, primarily USD and GBP. Foreign exchange risk arises from net investments in foreign operations.

ii. The Company’s businesses involve some non-functional currency operations (the Company’s functional currency: NTD). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

	December 31, 2025			Year ended December 31, 2025
	Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)	Sensitivity analysis	Effect on profit or loss
(Foreign currency: functional currency)				Extent of variation
Financial assets
Non-monetary Items
USD:NTD	$ 9,621	31.43	$ 302,399	-	$ -
GBP:NTD	159	42.33	6,737	-	-
	December 31, 2024			Year ended December 31, 2024
	Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)	Sensitivity analysis	Effect on profit or loss
(Foreign currency: functional currency)				Extent of variation
Financial assets
Non-monetary Items
USD:NTD	$ 10,935	32.79	$ 358,517	-	$ -
GBP:NTD	38	41.19	1,562	-	-

iii. The total exchange gain, including realised and unrealised arising from significant foreign exchange variation on the monetary items held by the Company for the years ended December 31, 2025 and 2024, amounted to $0 and $2, respectively.

Price risk

i. The Company is exposed to equity price risk from its investments classified on the consolidated balance sheet either as financial assets measured at fair value through profit or loss and financial assets measured at fair value through other comprehensive income. The Company is not exposed to commodity price risk. To manage its price risk arising from investments in equity securities, the Company has set stop-loss points and therefore does not expect to incur significant losses from equity price risk.

ii. The Company's investments in equity securities comprise domestic and foreign listed and unlisted stocks. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increased/decreased by 10% with all other variables held constant, post-tax profit for the years ended December 31, 2025 and 2024 would have increased/decreased by $5,964 and $5,875, respectively, as a result of gains/losses on equity securities classified as at fair value through profit or loss. Other components of equity would have increased/decreased by $1,451 and $1,272, respectively, as a result of other comprehensive income on equity investment classified as at fair value through other comprehensive income.

-46-

Cash flow and fair value interest rate risk

i. The Company’s interest rate risk arises from long-term borrowings. Long-term borrowings issued at variable rates expose the Company to cash flow interest rate risk, which is partially offset by cash and cash equivalents held at variable rates. The Company’s borrowings at variable rates are primarily denominated in NTD.

ii. If the borrowing interest rate had increased/decreased by 1% with all other variables held constant, profit, net of tax for the years ended December 31, 2025 and 2024 would have decreased/ increased by $14,042 and $13,520, respectively. The main factor is that changes in interest expense result from floating rate borrowings.

(b) Credit risk

The Company provides endorsements and guarantees based on the Company’s policies and procedures on endorsements and guarantees, either to subsidiaries. No collateral is requested for the endorsements and guarantees as the Company can control the credit risk of the subsidiary. The maximum credit risk is the guaranteed amount.

(c) Liquidity risk

i. Cash flow forecasting is performed in the operating entities of the Company and aggregated by Company treasury. Company treasury monitors rolling forecasts of the Company’s liquidity requirements to ensure it has sufficient cash to meet operational needs. Such forecasting takes into consideration the Company’s debt financing plans, covenant compliance, compliance with internal balance sheet ratio targets.

ii. The table below analyses the Company’s non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the expected or contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

Non-derivative financial liabilities:

December 31, 2025	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years
Short-term borrowings	$ 201,923	$ -	$ -
Notes payable	135	-	-
Other payables - related parties	39,686	-	-
Lease liability	7,200	7,200	3,000
Bonds payable and embedded derivative instruments	-	-	900,000
Long-term borrowings	281,197	1,184,010	-

Non-derivative financial liabilities:

December 31, 2024	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years
Short-term borrowings	$ 252,422	$ -	$ -
Notes payable	135	-	-
Other payables	22,097	-	-
Lease liability	7,200	7,200	10,200
Bonds payable and embedded derivative instruments	1,311,910	-	-
Long-term borrowings	31,732	227,331	1,183,633

(3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The fair value of the Company's investment in listed stocks is included in Level 1.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Company's investment in equity investment without active market is included in Level 3.

B. The carrying amount of a financial instrument not measured at fair value is a reasonable approximation of its fair value. Such financial instruments include cash and cash equivalents, other receivables (including related parties), short-term borrowings, notes payable, other payables, long-term borrowings (including current portion), bonds payable and lease liability.

C. The related information on financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

(a) The related information on the nature of the assets and liabilities is as follows:

December 31, 2025	Level 1	Level 2	Level 3	Total
Assets
Recurring fair value
measurements
Financial assets at fair
value through profit or loss
Equity securities	$ 15,996	$ -	$ -	$ 15,996
Privately offered funds	-	-	43,643	43,643
Financial assets at fair value
through other comprehensive
income
Equity securities	14,513	-	-	14,513
	$ 30,509	$ -	$ 43,643	$ 74,152
Liabilities
Recurring fair value
measurements
Financial liabilities at fair
value through profit or loss
Derivative instruments	$ -	$ -	$ 11,340	$ 11,340
December 31, 2024	Level 1	Level 2	Level 3	Total
Assets
Recurring fair value
measurements
Financial assets at fair
value through profit or loss
Equity securities	$ 49,669	$ -	$ -	$ 49,669
Privately offered funds	-	-	9,081	9,081
Financial assets at fair value
through other comprehensive
income
Equity securities	12,724	-	-	12,724
	$ 62,393	$ -	$ 9,081	$ 71,474

(b) The methods and assumptions the Company used to measure fair value are as follows:

i. Listed stocks are instruments whose fair values are measured using quoted market prices (that is, Level 1). The quoted market prices used for these stocks are the closing prices on the balance sheet date.

ii. Except for financial instruments with active markets, the fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes.

D. For the years ended December 31, 2025 and 2024, there was no transfer between Level 1 and Level 2.

E. The following chart is the movement of Level 3 for the years ended December 31, 2025 and 2024:

	2025
	Privately offered funds	Derivative financial instruments
At January 1	$ 9,081	$ -
Gains and losses recognised in profit or loss	62	( 3,766)
Acquired during the year	34,500	-
Convertible bonds issued during the year	-	( 7,470)
Convertible bonds converted during the year	-	( 104)
At December 31	$ 43,643	($ 11,340)
	2024
---	---	---
	Privately offered funds	Derivative financial instruments
At January 1	$ 5,231	$ 2,598
Gains and losses recognised in profit or loss	( 650)	( 2,574)
Acquired during the year	4,500	-
Convertible bonds converted during the year	-	( 24)
At December 31	$ 9,081	$ -

F. For the years ended December 31, 2025 and 2024, there was no transfer into or out from Level 3.

G. Financial accounting department is in charge of valuation procedures for fair value measurements being categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions and performing reviews regularly.

-49-

H. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

	Fair value at December 31, 2025	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:
Privately offered funds	$ 43,643	Net asset value	Not applicable	-	Not applicable
Hybrid instrument:
Convertible bonds	( 11,340)	Binomial Model	Volatility	41.00% (41.00%)	The higher the volatility, the higher the fair value; The higher the discount rate, the lower the fair value
			Discount rate	2.3401% (2.3401%)
	Fair value at December 31, 2024	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:
Privately offered funds	$ 9,081	Net asset value	Not applicable	-	Not applicable
Hybrid instrument:
Convertible bonds		- Binomial Model	Volatility	28.59% (28.59%)	The higher the volatility, the higher the fair value; The higher the discount rate, the lower the fair value
			Discount rate	1.5759% (1.5759%)

I. The Company has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. For financial assets and financial liabilities classified as Level 3, an increase or decrease in their valuation parameter by 1% would have no material impact on gain or loss and other comprehensive income as at December 31, 2025 and 2024.

-51-

13. SUPPLEMENTARY DISCLOSURES

(1) Significant transactions information

A. Loans to others: Refer to table 1.
B. Provision of endorsements and guarantees to others: Refer to table 2.
C. Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): None.
D. Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid-in capital or more: Refer to table 3.
E. Receivables from related parties reaching $100 million or 20% of paid-in capital or more: Refer to table 4.
F. Significant inter-company transactions during the reporting period: None exceeds $100 million.

(2) Information on investees

Information on investee companies (not including investees in Mainland China): Refer to table 5.

(3) Information on investments in Mainland China

A. Basic information: Refer to table 6.
B. Limits on investments in Mainland China: Refer to table 6.
C. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: None exceeds $100 million.

14. SEGMENT INFORMATION

Segment information is presented in the consolidated financial statements in accordance with the regulations of IFRS 8.

CHC Healthcare Group

Loans to others

For the year ended December 31, 2025

Expressed in thousands of NTD

(Except as otherwise indicated)

Table 1

No. (Note 1)	Creditor	Borrower	General ledger account	Is a related party	Maximum outstanding balance during the year ended December 31, 2025	Balance at December 31, 2025	Actual amount drawn down	Interest rate	Nature of loan	Amount of transactions with the borrower	Reason for short-term financing	Allowance for doubtful accounts	Collateral		Limit on loans granted to a single party (Note 2)	Ceiling on total loans granted (Note 3)
													Item	Value
0	The Company	Chiu Ho Medical System Co., Ltd.	Other receivables	Y	$ 300,000	$ 300,000	$ -	2%-3.5%	Short-term financing	$ -	Operation	$ -	None	$ -	$ 762,952	$ 3,051,809
0	The Company	Chiu Ho Scientific Co., Ltd.	Other receivables	Y	50,000	50,000	-	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	Shin-Ho Biotech Co., Ltd.	Other receivables	Y	600,000	600,000	250,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	Tomorrow Medical System Co., Ltd.	Other receivables	Y	450,000	450,000	200,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	Hsing-Yeh Biotechnology Co., Ltd.	Other receivables	Y	600,000	600,000	400,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	Chiu Ho Biotech Co., Ltd.	Other receivables	Y	60,000	60,000	20,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	Tong-Lin Instruments Co., Ltd.	Other receivables	Y	60,000	60,000	30,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	Hua Lin Instruments Co., Ltd.	Other receivables	Y	50,000	30,000	-	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	E Century Healthcare Corporation	Other receivables	Y	200,000	200,000	50,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
0	The Company	Treasure of Health Co., Ltd.	Other receivables	Y	250,000	250,000	110,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	762,952	3,051,809
1	Chiu Ho (CHINA) Medical Technology Co., Ltd.	CHC (Guangzhou) Medical Technology Co., Ltd.	Other receivables	Y	23,644	-	-	3.45%	Short-term financing	-	Operation	-	None	-	21,716	43,433
3	SenCare Healthcare Company	Let We Care Seniors Service Co., Ltd.	Other receivables	Y	10,000	5,000	2,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	59,149	118,298
4	Treasure of Health Co., Ltd.	K&M INTERNATIONAL Trading Co., Ltd.	Other receivables	Y	30,000	30,000	10,000	2%-3.5%	Short-term financing	-	Operation	-	None	-	72,158	144,317
						$ 2,635,000	$ 1,072,000

Note 1: The numbers filled in for the loans provided by the Company or subsidiaries are as follows:
(1) The Company is '0'.
(2) The subsidiaries are numbered in order starting from '1'.

Note 2: (1) In accordance with the Company's lending policies and procedures, the credit limit for each type of borrower is set as follows:

A. For borrowers with which the Company has a business relationship, the individual loan amount cannot exceed the total transaction amount with the Company in the most recent year.
B. For borrowers with short-term financing needs, the individual loan amount cannot exceed 10% of the Company's net assets according to the most recent financial statements.

(2) In accordance with the lending policies and procedures of the Company's subsidiary, the credit limit for each type of borrower is set as follows:

A. For borrowers with which the subsidiary has a business relationship, the individual loan amount cannot exceed the total transaction amount with the subsidiary in the most recent year.
B. The total loan amount granted to a single party cannot exceed 20% of the subsidiary's net assets according to the most recent financial statements.

Note 3: (1) Limit on total loans granted by the Company: Total loan amount cannot exceed 40% of the Company's net assets according to the most recent financial statements.

(2) Limit on total loans granted by the Company's subsidiary: Total loan amount cannot exceed 40% of the subsidiary's net assets according to the most recent financial statements.

Table 1, Page 2

CHC Healthcare Group

Provision of endorsements and guarantees to others

For the year ended December 31, 2025

Expressed in thousands of NTD

(Except as otherwise indicated)

Table 2

No. (Note 1)	Endorser/guarantor	Party being endorsed/guaranteed		Limit on endorsements/guarantees provided for a single party (Note 3)	Maximum outstanding endorsement/guarantee amount as of December 31, 2025	Outstanding endorsement/guarantee amount at December 31, 2025	Actual amount drawn down	Amount of endorsements/guarantees secured with collateral	Ratio of accumulated endorsement/guarantee amount to net asset value of the endorser/guarantor company	Ceiling on total amount of endorsements/guarantees provided (Note 4)	Provision of endorsements/guarantees by parent company to subsidiary (Note 5)	Provision of endorsements/guarantees by subsidiary to parent company (Note 5)	Provision of endorsements/guarantees to the party in Mainland China (Note 5)
		Company name	Relationship with the endorser/guarantor (Note 2)
0	The Company	Chiu Ho Medical System Co., Ltd.	2	$ 15,259,046	$ 850,000	$ 400,000	$ 108,691	$ -	5.24%	$ 22,888,569	Y	N	N
0	The Company	Tomorrow Medical System Co., Ltd.	2	15,259,046	1,288,000	988,800	934,842	-	12.96%	22,888,569	Y	N	N
0	The Company	Chiu Ho Scientific Co., Ltd.	2	15,259,046	80,000	80,000	28,523	-	1.05%	22,888,569	Y	N	N
0	The Company	Shin-Ho Biotech Co., Ltd.	2	15,259,046	771,000	771,000	498,672	-	10.11%	22,888,569	Y	N	N
0	The Company	CHC (Guangzhou) Medical Technology Co., Ltd.	2	15,259,046	33,720	33,720	16,456	-	0.44%	22,888,569	Y	N	N
1	Chiu Ho Medical System Co., Ltd.	The Company	3	9,892,189	1,106,687	1,106,687	940,684	1,106,687	22.37%	14,838,284	N	Y	N
1	Chiu Ho Medical System Co., Ltd.	Tomorrow Medical System Co., Ltd.	4	9,892,189	621,674	621,674	528,423	621,674	12.57%	14,838,284	N	N	N
						$ 4,001,881	$ 3,056,291	$ 1,728,361

Note 1: The numbers filled in for the endorsements/guarantees provided by the Company or subsidiaries are as follows:
(1) The Company is '0'.
(2) The subsidiaries are numbered in order starting from '1'.
Note 2: Relationship between the endorser/guarantor and the party being endorsed/guaranteed is classified into the following seven categories; fill in the number of category each case belongs to:
(1) Having business relationship.
(2) The endorser/guarantor parent company owns directly and indirectly more than $50\%$ voting shares of the endorsed/guaranteed subsidiary.
(3) The endorsed/guaranteed company owns directly and indirectly more than $50\%$ voting shares of the endorser/guarantor parent company.
(4) The endorser/guarantor parent company owns directly and indirectly more than $90\%$ voting shares of the endorsed/guaranteed company.
(5) Mutual guarantee of the trade made by the endorsed/guaranteed company or joint contractor as required under the construction contract.
(6) Due to joint venture, all shareholders provide endorsements/guarantees to the endorsed/guaranteed company in proportion to its ownership.
(7) Joint guarantee of the performance guarantee for pre-sold home sales contract as required under the Consumer Protection Act.
Note 3: (1) In accordance with the Company's policies and procedures on endorsements and guarantees, the endorsement or guarantee amount for a single party cannot exceed $200\%$ of the Company's net assets according to the most recent financial statements.
(2) In accordance with the policies and procedures on endorsements and guarantees provided by the Company's subsidiary, the endorsement or guarantee amount for a single party cannot exceed $200\%$ of the subsidiary's net assets according to the most recent financial statements.
(3) In accordance with the Company's policies and procedures on endorsements and guarantees, the total endorsement or guarantee amount for a single party provided by the Company and its subsidiaries cannot exceed $200\%$ of the Company's net assets according to the most recent financial statements.

Note 4: (1) In accordance with the Company's policies and procedures on endorsements and guarantees, the total endorsement and guarantee amount provided to external parties cannot exceed 300% of the Company's net assets according to the most recent financial statements.

(2) In accordance with policies and procedures on endorsements and guarantees provided by Company's subsidiary, the total endorsement and guarantee amount provided to external parties cannot exceed 300% of the subsidiary's net assets according to the most recent financial statements.

(3) In accordance with the Company's policies and procedures on endorsements and guarantees, the total endorsement and guarantee amount provided to external parties by the Company and its subsidiaries cannot exceed 300% of the net assets of the Company according to the most recent financial statements.

Note 5: Fill in "Y" for those cases of provision of endorsements/guarantees by listed parent company to subsidiary and provision by subsidiary to listed parent company, and provision to the party in Mainland China.

Table 2, Page 2

CHC Healthcare Group

Purchases or sales of goods from or to related parties reaching NT$100 million or 20% of paid-in capital or more

For the year ended December 31, 2025

Table 3

Purchaser/seller	Counterparty	Relationship with the counterparty	Transaction				Differences in transaction terms compared to third party transactions		Notes/accounts receivable (payable)		Footnote
			Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)
Hsing-Yeh Biotechnology Co., Ltd.	Yeezen General Hospital	Substantive related party	Sale of goods	$ 274,370	99%	6 months	-	-	$ 201,979	100%	Note

Note 1: Sales amount includes rental revenue.
Note 2: Notes and accounts receivable include lease payments receivable.

Expensesed in thousands of NTD

(Except as otherwise indicated)

Table 3, Page 1

CHC Healthcare Group

Receivables from related parties reaching NT$100 million or 20% of paid-in capital or more

December 31, 2025

Table 4
Expressed in thousands of NTD
(Except as otherwise indicated)

Creditor	Counterparty	Relationship with the counterparty	Balance as at December 31, 2025	Turnover rate (Note 1)	Overdue receivables		Amount collected subsequent to the balance sheet date (Note 2)	Allowance for doubtful accounts
					Amount	Action taken
Hsing-Yeh Biotechnology Co., Ltd.	Yeezen General Hospital	Substantive related party	Notes and accounts receivable (including lease payments receivable): $201,979	1.42	$ 62,264	In collection	$ 40,246	$ -
CHC Healthcare Group	Shin-Ho Biotech Co., Ltd.	Subsidiary	Other receivables: $250,000	0.00	-	-	-	-
CHC Healthcare Group	Tomorrow Medical System Co., Ltd.	Subsidiary	Other receivables: $200,000	0.00	-	-	-	-
CHC Healthcare Group	Hsing-Yeh Biotechnology Co., Ltd.	Subsidiary	Other receivables: $400,000	0.00	-	-	-	-
CHC Healthcare Group	Treasure of Health Co., Ltd.	Subsidiary	Other receivables: $110,000	0.00	-	-	-	-

Note 1: Turnover rate shown as 0.00 is because the amount is shown as other receivables in parent company only financial statement and is not applicable to turnover rate. Please refer to table 1 for the amount regarding loaning to others.
Note 2: The subsequent collections were amounts collected as of March 10, 2026.

Table 4, Page 1

CHC Healthcare Group

Information on investees

For the year ended December 31, 2025

Table 5

Expressed in thousands of NTD

(Except as otherwise indicated)

Investor	Investor	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2025			Net profit (loss) of the investee for the year ended December 31, 2025	Investment income (loss) recognised by the Company for the year ended December 31, 2025	Footnote
				Balance as at December 31, 2025	Balance as at December 31, 2024	Number of shares	Ownership (%)	Book value
The Company	Chiu Ho Medical System Co., Ltd.	Taiwan	Medical instrument sale, leasing and services	$ 2,956,388	$ 2,956,388	445,000,000	100.00%	$ 4,898,741	$ 173,672	$ 175,258	Subsidiary
The Company	Tomorrow Medical System Co., Ltd.	Taiwan	Medical instrument sale, leasing and services	613,484	613,484	90,800,000	100.00%	975,953	483 (	11,590)	Subsidiary
The Company	Chiu Ho Scientific Co., Ltd.	Taiwan	Ophthalmic equipment sale, leasing and services	151,422	151,422	9,853,841	100.00%	150,089	10,972	10,972	Subsidiary
The Company	Chiu Ho Biotech Co., Ltd.	Taiwan	Medical instrument leasing	47,182	186,822	6,000,000	100.00%	95,858	46,919	18,892	Subsidiary
The Company	Shin-Ho Biotech Co., Ltd.	Taiwan	Irradiation business	499,171	219,171	49,300,000	100.00%	273,661 (	75,937) (	75,937)	Subsidiary
The Company	Tong-Lin Instruments Co., Ltd.	Taiwan	Medical instrument leasing	281,183	281,183	31,000,000	100.00%	380,688	10,493	10,536	Subsidiary
The Company	Hua Lin Instruments Co., Ltd.	Taiwan	Medical instrument leasing	265,815	265,815	30,000,000	100.00%	400,824	23,227	23,297	Subsidiary
The Company	E Century Healthcare Corporation	Taiwan	Medical instrument sale and leasing	396,151	396,151	44,000,000	100.00%	659,580	55,336	55,336	Subsidiary
The Company	CHC Healthcare (UK) Limited	United Kingdom	Medical instrument sale	14,613	7,364	380,000	100.00%	6,737 (	2,413) (	2,413)	Subsidiary
The Company	CHC Healthcare (BVI) Limited	British Virgin Islands	Holdings and indirect investments	522,432	522,432	940	100.00%	302,399 (	35,758) (	35,758)	Subsidiary (Note 1)
The Company	Treasure of Health Co., Ltd.	Taiwan	Drug and health supplements sale	423,147	406,317	6,652,950	50.00%	457,155	86,084	34,497	Subsidiary

Table 5, Page 1

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2025			Net profit (loss) of the investee for the year ended December 31, 2025	Investment income (loss) recognised by the Company for the year ended December 31, 2025	Footnote
				Balance as at December 31, 2025	Balance as at December 31, 2024	Number of shares	Ownership (%)	Book value
CHC Healthcare (BVI) Limited	CHC Healthcare (HK) Limited	Hong Kong	Medical instrument sale, leasing and services	$ 4,080	$ 4,255	100,000	100.00%	$ 24,554	$ 92	$ 92	Subsidiary
Chiu Ho Medical System Co., Ltd.	SenCare Healthcare Company	Taiwan	Consulting service and elderly residence	194,000	194,000	19,400,000	65.99%	195,153	3,349	2,210	Subsidiary
Chiu Ho Medical System Co., Ltd.	PT CHC Medika Indonesia	Indonesia	Medical instrument leasing	5,358	5,358	2,566	100.00%	( 720) (	309) (	309)	Subsidiary (Note 1)
Chiu Ho Medical System Co., Ltd.	Hsing-Yeh Biotechnology Co., Ltd.	Taiwan	Medical instrument sale and leasing; drug sale	1,513,464	1,513,464	93,600,000	100.00%	1,622,660	46,475	45,681	Subsidiary
Hsing-Yeh Biotechnology Co., Ltd.	CHENG-HSIN Biotechnology Co., Ltd.	Taiwan	Management consulting services and retail sales of food products and drugs	12,000	12,000	1,200,000	40.00%	5,636 (	13,189) (	5,276)	Associate
SenCare Healthcare Company	CHC Long-term Care Corporation	Taiwan	Long-term care services	31,040	31,040	-	97.00%	28,272	852	826	Subsidiary (Note 2)
SenCare Healthcare Company	Let We Care Seniors Service Co., Ltd.	Taiwan	Senior services	4,946	4,946	471,700	74.88%	4,811 (	341) (	256)	Subsidiary
Treasure of Health Co., Ltd.	Exotic Pet Care Experts Co., Ltd.	Taiwan	Veterinary medical instrument leasing and drug sale	4,080	4,080	408,000	51.00%	5,691	3,119	1,596	Subsidiary
Treasure of Health Co., Ltd.	K&M INTERNATIONAL Trading Co., Ltd.	Taiwan	Daily necessities and beauty products sale	25,924	25,924	2,607,300	90.00%	28,270	2,334	2,102	Subsidiary
Treasure of Health Co., Ltd.	Happy Healthcare Company	Taiwan	Drug and health supplements sale	71,400	71,400	1,014,453	51.00%	75,597	10,606	2,217	Subsidiary

Note 1: Indirect investment company is organised as a limited liability company.
Note 2: Investee is organised as an association.

CHC Healthcare Group

Information on investments in Mainland China

For the year ended December 31, 2025

Table 6
Expressed in thousands of NTD
(Except as otherwise indicated)

Investee in Mainland China	Main business activities	Paid-in capital	Investment method (Note 1)	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the year ended December 31, 2025		Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2025	Net income of investee for the year ended December 31, 2025	Ownership held by the Company (direct or indirect)	Investment income (loss) recognised by the Company for the year ended December 31, 2025 (Note 2)	Book value of investments in Mainland China as of December 31, 2025
					Remitted to Mainland China	Remitted to Taiwan
CHC (Guangzhou) Medical Technology Co., Ltd.	Medical instrument sale, leasing and services	$ 298,672	(2) Indirect investment through CHC(BVI), a wholly-owned subsidiary of the Company	$ 298,672	$ -	$ -	$ 298,672	($ 30,488)	100% ($ 30,479)	$ 160,188	$ -
Chiu Ho (CHINA) Medical Technology Co., Ltd.	Medical instrument sale, leasing and services	237,121	(2) Indirect investment through CHC(BVI), a wholly-owned subsidiary of the Company	237,121	-	-	237,121	( 5,336)	100% ( 5,336)	108,584	-
Company name	Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2025	Investment amount approved by the Investment Commission of the Ministry of Economic affairs (MOEA)	Ceiling on investments in Mainland China imposed by the Investment Commission of MOEA (Note 3)
---	---	---	---
The Company	$ 535,793	$ 535,793	$ 4,829,847

Note 1: Investment methods are classified into the following three categories; fill in the number of category each case belongs to:
(1) Directly invest in a company in Mainland China.
(2) Through investing in an existing company in the third area, which then invested in the investee in Mainland China.
(3) Others
Note 2: Income (loss) recognised based on financial statements audited by independent auditors.
Note 3: Disclosed in accordance with the investment limits set forth in Jin-Shen-Zi No. 09704604680, issued by the Investment Comission of MOEA on August 29, 2008.
Note 4: The Company invested in the investees in Mainland China, including Neusoft CHC Medical Service Co., Ltd. through an existing company in Mainland China. Due to the existing company in Mainland China is a holding company, therefore it shall first submit an application for approval from Investment Commission of the Ministry of Economic Affairs (MOEA) for its reinvestments, but the approval from MOEA are not required for other investments.

Statement 1, Page 1

CHC HEALTHCARE GROUP

STATEMENT OF CASH AND CASH EQUIVALENTS

DECEMBER 31, 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Statement 1

Items	Description	Amount
Cash on hold		$ 88
Checking accounts		135
Demand deposits - NTD		267,335
Demand deposits - USD	USD $1,192.84 (Note), at exchange rate of 31.43	37
Demand deposits - HKD	HKD $327.18 (Note), at exchange rate of 4.04	1
		$ 267,596

(Note) Foreign currency is expressed in dollars.

CHC HEALTHCARE GROUP
STATEMENT OF INVESTMENTS ACCOUNTED FOR USING EQUITY METHOD
YEAR ENDED DECEMBER 31, 2025
(EXRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Statement 2

Name	Investment types	Opening balance		Additions (Note 1)		Reductions (Note 2)		Ending balance		As of December 31, 2025	Market price or value per share
		Number of shares (per thousand shares)	Amount	Number of shares (per thousand shares)	Amount	Number of shares (per thousand shares)	Amount	Number of Shares (per thousand shares)	Amount	Ownership (%)	Price (in dollars)	Total price	Pledged to others as collateral
Chiu Ho Medical System Co., Ltd.	Ordinary share	445,000	$4,835,997	-	$ 175,288	-	($ 112,544)	445,000	$ 4,898,741	100%	11.11	$ 4,946,095	None
Tomorrow Medical System Co., Ltd.	Ordinary share	90,800	1,021,266	-	-	-	( 45,313)	90,800	975,953	100%	10.92	991,607	None
Chiu Ho Scientific Co., Ltd.	Ordinary share	9,854	147,976	-	10,971	-	( 8,858)	9,854	150,089	100%	15.23	150,089	None
Chiu Ho Biotech Co., Ordinary share Ltd.	Ordinary share	19,964	237,614	-	18,892	( 13,964)	( 160,648)	6,000	95,858	100%	20.65	123,885	None
Shin-Ho Biotech Co., Ordinary share Ltd.	Ordinary share	21,300	69,598	28,000	280,000	-	( 75,937)	49,300	273,661	100%	5.55	273,661	None
Tong-Lin Instruments Ordinary share Co., Ltd.	Ordinary share	31,000	384,134	-	10,536	-	( 13,982)	31,000	380,688	100%	12.28	380,742	None
Hua Lin Instruments Ordinary share Co., Ltd.	Ordinary share	30,000	391,750	-	23,297	-	( 14,223)	30,000	400,824	100%	13.36	400,882	None
E Century Healthcare Ordinary share Corporation	Ordinary share	44,000	644,782	-	55,336	-	( 40,538)	44,000	659,580	100%	14.87	654,304	None
Treasure of Health Co., Ltd.	Ordinary share	6,462	415,228	191	58,765	-	( 16,838)	6,653	457,155	50%	27.12	180,397	None
CHC Healthcare (UK) Limited	Ordinary share	200	1,562	180	7,588	-	( 2,413)	380	6,737	100%	17.73	6,737	None
CHC Healthcare (BVI) Limited	Ordinary share	0.94	358,517	-	-	-	( 56,118)	0.94	302,399	100%	321,701.06	302,399	None
			$8,508,424		$ 640,673		($ 547,412)		$ 8,601,685			$ 8,410,798

Note 1: Includes investment loss arising from investments accounted for using equity method, subsidiaries' cash dividends paid to the parent company, changes in exchange differences on translation of foreign financial statements and changes in stock dividends from subsidiaries.
Note 2: Includes investment loss arising from investments accounted for using equity method, subsidiaries' cash dividends paid to the parent company, capital increase in the subsidiaries not in proportion to shareholding, acquisition of the subsidiary's redeemable liabilities, reorganization of subsidiaries, changes in exchange differences on translation of foreign financial statements and shares returned from reduction in subsidiaries.

Statement 2, Page 1

Statement 3, Page 1

CHC HEALTHCARE GROUP

STATEMENT OF BONDS PAYABLE

DECEMBER 31, 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Bonds	Trustees	Issuance date	Coupon rate	Amount				Repayment	Pledged to others as collateral
				Face value of issuance	Balance at December 31, 2025	Unamortised discounts	Carrying value
Fifth domestic secured convertible bonds	Bank SinoPac	2025.06.20	0%	$ 900,000	$ 900,000	($ 96,490)	$ 803,510	Please refer to Note 6 (7)	None

Statement 4, Page 1

CHC HEALTHCARE GROUP

STATEMENT OF OPERATING COSTS

YEAR ENDED DECEMBER 31, 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Statement 4

Items	Amount	Notes
Wages and salaries	$ 71,855
Directors’ remuneration	6,516
Cost of services	5,195
Depreciation	7,208
Other expenses	18,107	None of the balances of each remaining item is greater than 5% of this account balance.
	$ 108,881

CHC HEALTHCARE GROUP
SUMMARY STATEMENT OF CURRENT PERIOD EMPLOYEE BENEFITS,
DEPRECIATION AND AMORTIZATION EXPENSES BY FUNCTION
YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Statement 5

Nature	Function	Year ended December 31, 2025			Year ended December 31, 2024
		Classified as Operating Costs	Classified as Operating Expenses	Total	Classified as Operating Costs	Classified as Operating Expenses	Total
Employee benefit expense
Wages and salaries	$	71,855	$ -	$ 71,855	$ 81,537	$ -	$ 81,537
Labour and health insurance fees		6,023	-	6,023	5,774	-	5,774
Pension costs		2,531	-	2,531	2,431	-	2,431
Directors’ remuneration		6,516	-	6,516	6,259	-	6,259
Other personnel expenses		2,392	-	2,392	2,361	-	2,361
	$	89,317	$ -	$ 89,317	$ 98,362	$ -	$ 98,362
Depreciation charge	$	7,208	$ -	$ 7,208	$ 7,206	$ -	$ 7,206
Amortisation charge	$	213	$ -	$ 213	$ 197	$ -	$ 197

Note:
1. As of December 31, 2025 and 2024, the Company had 61 and 60 employees, excluding 5 director for both years.
2. A company whose stock is listed for trading on the stock exchange or over-the-counter securities exchange shall additionally disclose the following information :
(1) Average employee benefit expense in current year was $1,479 ((Total employee benefit expense in current year–Total directors’ compensation in current year)/(Number of employees in current year–Number of non-employee directors in current year)).
Average employee benefit expense in previous year was $1,675 ((Total employee benefit expense in previous year–Total directors’ compensation in previous year)/ (Number of employees in previous year – Number of non-employee directors in previous year)).
(2) Average employee salaries in current year was $1,283 (Total employee salaries in current year / (Number of employees in current year - Number of non-employee directors in current year)).
Average employee salaries in previous year was $1,482 (Total employee salaries in previous year / (Number of employees in previous year - Number of non-employee directors in previous year)).
(3) Adjustments of average employee salaries was (13.43%) ((Average employee salaries in current year- Average employee salaries in previous year)/ Average employee salaries in previous year).
(4) The Company’s Salary and Compensation Policy (including directors, supervisors, managers and employees) is as follows:
A. Managers and employees: Compensation that the Company paid to the employees includes salary, holiday bonus, performance bonus and allowance. Pay level is determined in accordance with employees’ responsibility and contribution to the Company and by reference to the general pay levels in the industry.
B. Directors: Policy of the remuneration that the Company paid to the directors is stipulated in the Articles of Incorporation of the Company and is approved by the shareholders at their meeting. In accordance with the Articles of Incorporation of the Company, when the directors conduct the Company’s business, pay level is determined in accordance with directors’ participation and value of contribution in the Company’s operation and by reference to the general pay levels in the industry. The Company distributes directors’ remuneration if it has any profit for the current year in accordance with the Article 24-1 of Incorporation of the Company.

Statement 5, Page 1

AI assistant

CHC — Audit Report / Information 2025

52389_rns_2026-05-18_21c9fdf4-2a3e-4987-b9e5-de15f27dd2a4.pdf

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

Opinion

Basis for opinion

Key audit matters

Assessment of investments accounted for using equity method

Impairment assessment of Treasure of Health Co., Ltd., Chiu Ho Medical System Co., Ltd., and Tomorrow Medical System Co., Ltd., the Company’s subsidiaries

Impairment assessment of goodwill

Description

How our audit addressed the matter

Assessment of Reasonableness of Purchase Price Allocation for Business Combination

Description

How our audit addressed the matter

Impairment assessment of property, plant and equipment

Description

How our audit addressed the matter

Responsibilities of management and those charged with governance for the parent company only financial statements

Auditors’ responsibilities for the audit of the parent company only financial statements

CHC HEALTHCARE GROUP

PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY

YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

6. DETAILS OF SIGNIFICANT ACCOUNTS

(5) Leasing arrangements-lessee

(6) Short-term borrowings

(7) Bonds payable

(9) Pensions

(10) Share-based payment

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

(2) Names of related parties and relationship

Price risk

Cash flow and fair value interest rate risk

(b) Credit risk

(c) Liquidity risk

Non-derivative financial liabilities:

13. SUPPLEMENTARY DISCLOSURES

14. SEGMENT INFORMATION

CHC Healthcare Group

Information on investees

CHC HEALTHCARE GROUP

STATEMENT OF CASH AND CASH EQUIVALENTS

DECEMBER 31, 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

CHC HEALTHCARE GROUP

STATEMENT OF BONDS PAYABLE

DECEMBER 31, 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

CHC HEALTHCARE GROUP

STATEMENT OF OPERATING COSTS

YEAR ENDED DECEMBER 31, 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

More from CHC

CHC Audit Report / Information 2025